{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:52:24Z","timestamp":1793393544263,"version":"4.5.0"},"reference-count":604,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403017"],"award-info":[{"award-number":["82403017"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272990"],"award-info":[{"award-number":["82272990"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RGC Postdoctoral Fellowship Scheme","award":["UGC\/GEN\/562\/3"],"award-info":[{"award-number":["UGC\/GEN\/562\/3"]}]},{"name":"NSFC-RGC Joint Research Scheme","award":["N_CUHK448\/23"],"award-info":[{"award-number":["N_CUHK448\/23"]}]},{"name":"CUHK Direct Research Grant","award":["2024.066"],"award-info":[{"award-number":["2024.066"]}]},{"name":"RGC General Research Fund","award":["CUHK14122725"],"award-info":[{"award-number":["CUHK14122725"]}]},{"name":"Hebei Provincial Major Science and Technology Support Plan International Scientific and Technological Cooperation\/Hong Kong, Macau, and Taiwan Science and Technology Cooperation Project","award":["25297706D"],"award-info":[{"award-number":["25297706D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology by combining the target specificity of antibodies with the high potency of diverse cytotoxic payloads. This review provides an integrative overview of ADCs, spanning from molecular design to clinical translation. We dissect the structural components, antibodies, linkers, and payloads, and elucidate their impact on pharmacokinetics, tumor selectivity, and therapeutic index. Mechanistic pathways, including antigen recognition, receptor-mediated internalization, payload release, and immunogenic cell death (ICD), are highlighted to provide context for ADC function. Clinically, ADCs have demonstrated efficacy across hematologic and solid malignancies, with 15 Food and Drug Administration (FDA) approvals and an expanding investigational pipeline. However, challenges persist, including antigen heterogeneity, resistance mechanisms, systemic toxicities, and manufacturing complexities. Emerging innovations such as bispecific ADCs, immune-stimulatory payloads, AI-guided design, and nanotechnology-enhanced delivery are reshaping the ADC landscape. Finally, we emphasize the necessity of diagnostic precision and rational combination strategies, while highlighting emerging innovations that collectively shape the future direction of next-generation ADC therapeutics.<\/jats:p>","DOI":"10.1186\/s12943-025-02489-2","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:15:07Z","timestamp":1762164907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["Antibody\u2013drug conjugates in cancer therapy: current landscape, challenges, and future directions"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2430-7934","authenticated-orcid":false,"given":"Bonan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5008-2153","authenticated-orcid":false,"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K. K.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M. K.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4919-3707","authenticated-orcid":false,"given":"Ka Fai","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-677X","authenticated-orcid":false,"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2489_CR1","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409\u201336.","journal-title":"CA Cancer J Clin"},{"key":"2489_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2489_CR3","first-page":"224","volume":"74","author":"N Jokhadze","year":"2024","unstructured":"Jokhadze N, Das A, Dizon DS. Global cancer statistics: A healthy population relies on population health. CA Cancer J Clin. 2024;74:224\u20136.","journal-title":"CA Cancer J Clin"},{"key":"2489_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc1529","volume":"5","author":"BA Chabner","year":"2005","unstructured":"Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65\u201372.","journal-title":"Nat Rev Cancer"},{"key":"2489_CR5","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643\u201353.","journal-title":"Cancer Res"},{"key":"2489_CR6","doi-asserted-by":"crossref","unstructured":"Jang JY, Kim D, Kim ND. Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors. Int J Mol Sci. 2023;24:8457.","DOI":"10.3390\/ijms24098457"},{"key":"2489_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960317","volume":"12","author":"CM Tilsed","year":"2022","unstructured":"Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022;12:960317.","journal-title":"Front Oncol"},{"key":"2489_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jconrel.2015.08.041","volume":"219","author":"D Liu","year":"2015","unstructured":"Liu D, Auguste DT. Cancer targeted therapeutics: From molecules to drug delivery vehicles. J Control Release. 2015;219:632\u201343.","journal-title":"J Control Release"},{"key":"2489_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/jamaoncol.2024.0194","volume":"10","author":"A Tibau","year":"2024","unstructured":"Tibau A, Hwang TJ, Molto C, Avorn J, Kesselheim AS. Clinical value of molecular targets and FDA-approved genome-targeted cancer therapies. JAMA Oncol. 2024;10:634\u201341.","journal-title":"JAMA Oncol"},{"key":"2489_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"2489_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-09-2084","volume":"16","author":"RS Finn","year":"2010","unstructured":"Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res. 2010;16:390\u20137.","journal-title":"Clin Cancer Res"},{"key":"2489_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","volume":"395","author":"PL Bedard","year":"2020","unstructured":"Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395:1078\u201388.","journal-title":"Lancet"},{"key":"2489_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237\u201351.","journal-title":"Nat Rev Cancer"},{"key":"2489_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.actbio.2021.04.054","volume":"129","author":"TA Tabish","year":"2021","unstructured":"Tabish TA, Narayan RJ. Mitochondria-targeted graphene for advanced cancer therapeutics. Acta Biomater. 2021;129:43\u201356.","journal-title":"Acta Biomater"},{"key":"2489_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.","journal-title":"Signal Transduct Target Ther"},{"key":"2489_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"2489_CR17","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","volume":"27","author":"AW Tolcher","year":"2016","unstructured":"Tolcher AW. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol. 2016;27:2168\u201372.","journal-title":"Ann Oncol"},{"key":"2489_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33\u201346.","journal-title":"Protein Cell"},{"key":"2489_CR19","doi-asserted-by":"crossref","unstructured":"Theocharopoulos C, Lialios PP, Samarkos M, Gogas H, Ziogas DC. Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. Vaccines (Basel). 2021;9:1111.","DOI":"10.3390\/vaccines9101111"},{"key":"2489_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"2489_CR21","doi-asserted-by":"crossref","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35:e00225.","DOI":"10.1042\/BSR20150089"},{"key":"2489_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acs.bioconjchem.2c00177","volume":"33","author":"SS Matikonda","year":"2022","unstructured":"Matikonda SS, McLaughlin R, Shrestha P, Lipshultz C, Schnermann MJ. Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold. Bioconjug Chem. 2022;33:1241\u201353.","journal-title":"Bioconjug Chem"},{"key":"2489_CR23","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","volume":"10","author":"P Zhao","year":"2020","unstructured":"Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020;10:1589\u2013600.","journal-title":"Acta Pharm Sin B"},{"key":"2489_CR24","doi-asserted-by":"crossref","unstructured":"Gogia P, Ashraf H, Bhasin S, Xu Y. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers (Basel). 2023;15:3886.","DOI":"10.3390\/cancers15153886"},{"key":"2489_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/2472555220912955","volume":"25","author":"L Gauzy-Lazo","year":"2020","unstructured":"Gauzy-Lazo L, Sassoon I, Brun MP. Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations. SLAS Discov. 2020;25:843\u201368.","journal-title":"SLAS Discov"},{"key":"2489_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","volume":"44","author":"DY Ruan","year":"2024","unstructured":"Ruan DY, Wu HX, Meng Q, Xu RH. Development of antibody-drug conjugates in cancer: Overview and prospects. Cancer Commun (Lond). 2024;44:3\u201322.","journal-title":"Cancer Commun (Lond)"},{"key":"2489_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2025.102054","volume":"14","author":"AZ Alrosan","year":"2025","unstructured":"Alrosan AZ, Dmour I, Rataan AO, Heilat GB, Alrosan K. Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer. Toxicol Rep. 2025;14:102054.","journal-title":"Toxicol Rep"},{"key":"2489_CR28","doi-asserted-by":"crossref","unstructured":"Gandullo-S\u00e1nchez L, Oca\u00f1a A, Pandiella A. Generation of Antibody-Drug Conjugate Resistant Models. Cancers (Basel). 2021;13:4631.","DOI":"10.3390\/cancers13184631"},{"key":"2489_CR29","doi-asserted-by":"crossref","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. 2023;24:9674.","DOI":"10.3390\/ijms24119674"},{"key":"2489_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter FW, Barker HR, Lipert B, Roth\u00e9 F, Gebhart G, Piccart-Gebhart MJ, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122:603\u201312.","journal-title":"Br J Cancer"},{"key":"2489_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41523-023-00578-3","volume":"9","author":"J Ma","year":"2023","unstructured":"Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4\/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023;9:74.","journal-title":"NPJ Breast Cancer"},{"key":"2489_CR32","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.7150\/ijbs.93697","volume":"20","author":"R Birnboim-Perach","year":"2024","unstructured":"Birnboim-Perach R, Benhar I. Using combination therapy to overcome diverse challenges of immune checkpoint inhibitors treatment. Int J Biol Sci. 2024;20:3911\u201322.","journal-title":"Int J Biol Sci"},{"key":"2489_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2174\/1568009622666220224110538","volume":"22","author":"BA Teicher","year":"2022","unstructured":"Teicher BA, Morris J. Antibody-drug conjugate targets, drugs, and linkers. Curr Cancer Drug Targets. 2022;22:463\u2013529.","journal-title":"Curr Cancer Drug Targets"},{"key":"2489_CR34","doi-asserted-by":"crossref","unstructured":"Larrosa C, Mora J, Cheung NK. Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2. Cancers (Basel). 2023;15:3729.","DOI":"10.3390\/cancers15143729"},{"key":"2489_CR35","first-page":"18","volume":"5","author":"X Zhang","year":"2022","unstructured":"Zhang X, Huang AC, Chen F, Chen H, Li L, Kong N, et al. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antib Ther. 2022;5:18\u201329.","journal-title":"Antib Ther"},{"key":"2489_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","volume":"43","author":"H Huang","year":"2025","unstructured":"Huang H, Zhou Y, Shang C, Zhang Y, Shen Y. A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs. Invest New Drugs. 2025;43:262\u201375.","journal-title":"Invest New Drugs"},{"key":"2489_CR37","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12:3528.","journal-title":"Nat Commun"},{"key":"2489_CR38","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1535-7163.MCT-24-0078","volume":"23","author":"H Yue","year":"2024","unstructured":"Yue H, Xu H, Ma L, Li X, Yang B, Wang X, et al. A DXd\/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation. Mol Cancer Ther. 2024;23:1639\u201351.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR39","doi-asserted-by":"crossref","unstructured":"Zhao RJ, Fan XX. Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy. Int J Mol Sci. 2025;26:1440.","DOI":"10.3390\/ijms26041440"},{"key":"2489_CR40","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","volume":"69","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu Y, Li G, Yang Z, Han C, Sun X, et al. Targeting the undruggables-the power of protein degraders. Sci Bull (Beijing). 2024;69:1776\u201397.","journal-title":"Sci Bull (Beijing)"},{"key":"2489_CR41","doi-asserted-by":"crossref","unstructured":"Kang DH, Lee J, Im S, Chung C. Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure. Cancers (Basel). 2024;16:3996.","DOI":"10.3390\/cancers16233996"},{"key":"2489_CR42","doi-asserted-by":"crossref","unstructured":"Bandara S, Raveendran S. Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges. Cancers (Basel). 2025;17:821.","DOI":"10.3390\/cancers17050821"},{"key":"2489_CR43","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165\u201382.","journal-title":"CA Cancer J Clin"},{"key":"2489_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","volume":"9","author":"J Fuentes-Antr\u00e1s","year":"2023","unstructured":"Fuentes-Antr\u00e1s J, Genta S, Vijenthira A, Siu LL. Antibody-drug conjugates: in search of partners of choice. Trends Cancer. 2023;9:339\u201354.","journal-title":"Trends Cancer"},{"key":"2489_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16:3.","journal-title":"J Hematol Oncol"},{"key":"2489_CR46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"BQ Shen","year":"2012","unstructured":"Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30:184\u20139.","journal-title":"Nat Biotechnol"},{"key":"2489_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"2489_CR48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394:793\u2013804.","journal-title":"Lancet"},{"key":"2489_CR49","doi-asserted-by":"crossref","unstructured":"Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-Drug Conjugates: The New Frontier of Chemotherapy. Int J Mol Sci. 2020;21:5510.","DOI":"10.3390\/ijms21155510"},{"key":"2489_CR50","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40259-018-0302-5","volume":"32","author":"E Khera","year":"2018","unstructured":"Khera E, Thurber GM. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates. BioDrugs. 2018;32:465\u201380.","journal-title":"BioDrugs"},{"key":"2489_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"2489_CR52","doi-asserted-by":"crossref","unstructured":"Indini A, Rijavec E, Grossi F. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Int J Mol Sci. 2021;22:4774.","DOI":"10.3390\/ijms22094774"},{"key":"2489_CR53","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888\u201397.","journal-title":"Clin Cancer Res"},{"key":"2489_CR54","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458\u201365.","journal-title":"Blood"},{"key":"2489_CR55","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29:1335\u201344.","journal-title":"Drug Deliv"},{"key":"2489_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y, et al. A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers. Mol Cancer. 2024;23:62.","journal-title":"Mol Cancer"},{"key":"2489_CR57","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423\u201333.","journal-title":"Lancet"},{"key":"2489_CR58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169\u201377.","journal-title":"Breast"},{"key":"2489_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer Cell. 2016;29:117\u201329.","journal-title":"Cancer Cell"},{"key":"2489_CR60","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1535-7163.MCT-22-0414","volume":"22","author":"AE Perez Bay","year":"2023","unstructured":"Perez Bay AE, Faulkner D, DaSilva JO, Young TM, Yang K, Giurleo JT, et al. A Bispecific METxMET Antibody-Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes. Mol Cancer Ther. 2023;22:357\u201370.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR61","doi-asserted-by":"publisher","first-page":"2302386","DOI":"10.1080\/19420862.2024.2302386","volume":"16","author":"A Evers","year":"2024","unstructured":"Evers A, Krah S, Demir D, Gaa R, Elter D, Schroeter C, et al. Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET. MAbs. 2024;16:2302386.","journal-title":"MAbs"},{"key":"2489_CR62","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925\u201332.","journal-title":"Nat Biotechnol"},{"key":"2489_CR63","doi-asserted-by":"crossref","unstructured":"Zhou Q. Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins. Molecules. 2023;28:917.","DOI":"10.3390\/molecules28030917"},{"key":"2489_CR64","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","volume":"28","author":"Y Gu","year":"2024","unstructured":"Gu Y, Zhao Q. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors. Mol Diagn Ther. 2024;28:669\u2013702.","journal-title":"Mol Diagn Ther"},{"key":"2489_CR65","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"2489_CR66","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41388-022-02209-w","volume":"41","author":"G Qiao","year":"2022","unstructured":"Qiao G, Kone LB, Phillips EH, Lee SS, Brown GE, Khetani SR, et al. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. Oncogene. 2022;41:2054\u201368.","journal-title":"Oncogene"},{"key":"2489_CR67","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","volume":"124","author":"A Singh","year":"2021","unstructured":"Singh A, Dees S, Grewal IS. Overcoming the challenges associated with CD3+ T-cell redirection in cancer. Br J Cancer. 2021;124:1037\u201348.","journal-title":"Br J Cancer"},{"key":"2489_CR68","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B. 2024;14:1965\u201386.","journal-title":"Acta Pharm Sin B"},{"key":"2489_CR69","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1021\/acs.jmedchem.7b01430","volume":"61","author":"B Wei","year":"2018","unstructured":"Wei B, Gunzner-Toste J, Yao H, Wang T, Wang J, Xu Z, et al. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity. J Med Chem. 2018;61:989\u20131000.","journal-title":"J Med Chem"},{"key":"2489_CR70","doi-asserted-by":"crossref","unstructured":"Mahmood I. Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies (Basel). 2021;10:20.","DOI":"10.3390\/antib10020020"},{"key":"2489_CR71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.01.005","volume":"128","author":"A Paci","year":"2020","unstructured":"Paci A, Desnoyer A, Delahousse J, Blondel L, Maritaz C, Chaput N, et al. Pharmacokinetic\/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. Eur J Cancer. 2020;128:107\u201318.","journal-title":"Eur J Cancer"},{"key":"2489_CR72","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48:4361\u201374.","journal-title":"Chem Soc Rev"},{"key":"2489_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-Drug Conjugates: A Comprehensive Review. Mol Cancer Res. 2020;18:3\u201319.","journal-title":"Mol Cancer Res"},{"key":"2489_CR74","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: recent advances in linker chemistry. Acta Pharm Sin B. 2021;11:3889\u2013907.","journal-title":"Acta Pharm Sin B"},{"key":"2489_CR75","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280\u201390.","journal-title":"Cancer Res"},{"key":"2489_CR76","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1021\/bc5005747","volume":"26","author":"M Dorywalska","year":"2015","unstructured":"Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem. 2015;26:650\u20139.","journal-title":"Bioconjug Chem"},{"key":"2489_CR77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/bc9002019","volume":"21","author":"L Ducry","year":"2010","unstructured":"Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21:5\u201313.","journal-title":"Bioconjug Chem"},{"key":"2489_CR78","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/anie.201307628","volume":"53","author":"RV Chari","year":"2014","unstructured":"Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53:3796\u2013827.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2489_CR79","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/bc5004982","volume":"26","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015;26:176\u201392.","journal-title":"Bioconjug Chem"},{"key":"2489_CR80","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1039\/C6SC01831A","volume":"8","author":"TH Pillow","year":"2017","unstructured":"Pillow TH, Sadowsky JD, Zhang D, Yu SF, Del Rosario G, Xu K, et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci. 2017;8:366\u201370.","journal-title":"Chem Sci"},{"key":"2489_CR81","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1021\/bc100480a","volume":"22","author":"BA Kellogg","year":"2011","unstructured":"Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem. 2011;22:717\u201327.","journal-title":"Bioconjug Chem"},{"key":"2489_CR82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/bc900315y","volume":"21","author":"HK Erickson","year":"2010","unstructured":"Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010;21:84\u201392.","journal-title":"Bioconjug Chem"},{"key":"2489_CR83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47\u201358.","journal-title":"Bioconjug Chem"},{"key":"2489_CR84","doi-asserted-by":"publisher","first-page":"397","DOI":"10.18632\/oncotarget.924","volume":"4","author":"J Feld","year":"2013","unstructured":"Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget. 2013;4:397\u2013412.","journal-title":"Oncotarget"},{"key":"2489_CR85","doi-asserted-by":"crossref","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020;25:4764.","DOI":"10.3390\/molecules25204764"},{"key":"2489_CR86","first-page":"3336","volume":"53","author":"LM Hinman","year":"1993","unstructured":"Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53:3336\u201342.","journal-title":"Cancer Res"},{"key":"2489_CR87","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/jm500766w","volume":"57","author":"JM Lambert","year":"2014","unstructured":"Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57:6949\u201364.","journal-title":"J Med Chem"},{"key":"2489_CR88","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1389450117666160527142544","volume":"19","author":"P Sanchez-Moreno","year":"2018","unstructured":"Sanchez-Moreno P, Ortega-Vinuesa JL, Peula-Garcia JM, Marchal JA, Boulaiz H. Smart drug-delivery systems for cancer nanotherapy. Curr Drug Targets. 2018;19:339\u201359.","journal-title":"Curr Drug Targets"},{"key":"2489_CR89","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.actbio.2017.11.007","volume":"65","author":"M Mart\u00ednez-Carmona","year":"2018","unstructured":"Mart\u00ednez-Carmona M, Lozano D, Colilla M, Vallet-Reg\u00ed M. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. Acta Biomater. 2018;65:393\u2013404.","journal-title":"Acta Biomater"},{"key":"2489_CR90","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","volume":"17","author":"BA Teicher","year":"2011","unstructured":"Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17:6389\u201397.","journal-title":"Clin Cancer Res"},{"key":"2489_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmch.2023.10.001","volume":"62","author":"AD Hobson","year":"2023","unstructured":"Hobson AD. Antibody drug conjugates beyond cytotoxic payloads. Prog Med Chem. 2023;62:1\u201359.","journal-title":"Prog Med Chem"},{"key":"2489_CR92","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.2174\/1568026615666141208111253","volume":"14","author":"SM Gromek","year":"2015","unstructured":"Gromek SM, Balunas MJ. Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates. Curr Top Med Chem. 2015;14:2822\u201334.","journal-title":"Curr Top Med Chem"},{"key":"2489_CR93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","volume":"18","author":"L Shefet-Carasso","year":"2015","unstructured":"Shefet-Carasso L, Benhar I. Antibody-targeted drugs and drug resistance\u2013challenges and solutions. Drug Resist Updat. 2015;18:36\u201346.","journal-title":"Drug Resist Updat"},{"key":"2489_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2021.10.006","volume":"340","author":"D Singh","year":"2021","unstructured":"Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: from lab to clinical development. J Control Release. 2021;340:1\u201334.","journal-title":"J Control Release"},{"key":"2489_CR95","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"2489_CR96","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/01480545.2021.2005085","volume":"46","author":"J Jiang","year":"2023","unstructured":"Jiang J, Li S, Tang N, Wang L, Xin W, Li S. Preclinical safety profile of RC88-ADC: a novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E. Drug Chem Toxicol. 2023;46:24\u201334.","journal-title":"Drug Chem Toxicol"},{"key":"2489_CR97","first-page":"422","volume":"64","author":"G Bianchi","year":"2014","unstructured":"Bianchi G, Anderson KC. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64:422\u201344.","journal-title":"CA Cancer J Clin"},{"key":"2489_CR98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-024-01055-1","volume":"14","author":"AA Almodovar Diaz","year":"2024","unstructured":"Almodovar Diaz AA, Alouch SS, Chawla Y, Gonsalves WI. The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: a comprehensive review. Blood Lymphat Cancer. 2024;14:71\u201387.","journal-title":"Blood Lymphat Cancer"},{"key":"2489_CR99","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/1535-7163.MCT-21-0915","volume":"21","author":"JA Scribner","year":"2022","unstructured":"Scribner JA, Hicks SW, Sinkevicius KW, Yoder NC, Diedrich G, Brown JG, et al. Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Mol Cancer Ther. 2022;21:1047\u201359.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR100","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","volume":"22","author":"HE Marei","year":"2022","unstructured":"Marei HE, Cenciarelli C, Hasan A. Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022;22:255.","journal-title":"Cancer Cell Int"},{"key":"2489_CR101","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/1535-7163.MCT-21-0851","volume":"21","author":"WR Wiedemeyer","year":"2022","unstructured":"Wiedemeyer WR, Gavrilyuk J, Schammel A, Zhao X, Sarvaiya H, Pysz M, et al. ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. Mol Cancer Ther. 2022;21:986\u201398.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR102","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","volume":"26","author":"HP Yao","year":"2021","unstructured":"Yao HP, Zhao H, Hudson R, Tong XM, Wang MH. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress. Drug Discov Today. 2021;26:1857\u201374.","journal-title":"Drug Discov Today"},{"key":"2489_CR103","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1039\/D2MD00194B","volume":"13","author":"AM Joseph","year":"2022","unstructured":"Joseph AM, Nahar K, Daw S, Hasan MM, Lo R, Le TBK, et al. Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage. RSC Med Chem. 2022;13:1621\u201333.","journal-title":"RSC Med Chem"},{"key":"2489_CR104","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12885-021-08403-5","volume":"21","author":"MG Anderson","year":"2021","unstructured":"Anderson MG, Zhang Q, Rodriguez LE, Hecquet CM, Donawho CK, Ansell PJ, et al. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer. 2021;21:681.","journal-title":"BMC Cancer"},{"key":"2489_CR105","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","volume":"19","author":"HL Perez","year":"2014","unstructured":"Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19:869\u201381.","journal-title":"Drug Discov Today"},{"key":"2489_CR106","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","volume":"21","author":"E Khera","year":"2022","unstructured":"Khera E, Dong S, Huang H, de Bever L, van Delft FL, Thurber GM. Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates. Mol Cancer Ther. 2022;21:310\u201321.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR107","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:51.","journal-title":"J Hematol Oncol"},{"key":"2489_CR108","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6:34\u201345.","journal-title":"MAbs"},{"key":"2489_CR109","doi-asserted-by":"publisher","first-page":"175883592413094","DOI":"10.1177\/17588359241309461","volume":"17","author":"D Izzo","year":"2025","unstructured":"Izzo D, Ascione L, Guidi L, Marsicano RM, Koukoutzeli C, Trapani D, et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Ther Adv Med Oncol. 2025;17:17588359241309460.","journal-title":"Ther Adv Med Oncol"},{"key":"2489_CR110","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"2489_CR111","doi-asserted-by":"crossref","unstructured":"Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, et al. Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021;22:1551.","DOI":"10.3390\/ijms22041551"},{"key":"2489_CR112","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, et al. Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer. Clin Cancer Res. 2024;30:2917\u201324.","journal-title":"Clin Cancer Res"},{"key":"2489_CR113","doi-asserted-by":"crossref","unstructured":"Najdi T, Awad L, Chartouni A, Soueidy C, Kourie H. Navigating antibody\u2012drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies. Invest New Drugs. 2025;43:466-503.","DOI":"10.1007\/s10637-025-01525-8"},{"key":"2489_CR114","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-23-3110","volume":"30","author":"A Cheung","year":"2024","unstructured":"Cheung A, Chenoweth AM, Johansson A, Laddach R, Guppy N, Trendell J, et al. Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clin Cancer Res. 2024;30:3298\u2013315.","journal-title":"Clin Cancer Res"},{"key":"2489_CR115","first-page":"1","volume":"40","author":"V Boni","year":"2020","unstructured":"Boni V, Sharma MR, Patnaik A. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads. Am Soc Clin Oncol Educ Book. 2020;40:1\u201317.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2489_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708806","volume":"12","author":"JC Umotoy","year":"2021","unstructured":"Umotoy JC, de Taeye SW. Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure. Front Immunol. 2021;12:708806.","journal-title":"Front Immunol"},{"key":"2489_CR117","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2023.05.031","volume":"359","author":"J Choi","year":"2023","unstructured":"Choi J, Jang H, Choi J, Choi Y, Yang Y, Shim MK, et al. Immune checkpoint-targeted drug conjugates: a promising tool for remodeling tumor immune microenvironment. J Control Release. 2023;359:85\u201396.","journal-title":"J Control Release"},{"key":"2489_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107341","volume":"207","author":"C Li","year":"2024","unstructured":"Li C, Shi K, Zhao S, Liu J, Zhai Q, Hou X, et al. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions. Pharmacol Res. 2024;207:107341.","journal-title":"Pharmacol Res"},{"key":"2489_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116709","volume":"276","author":"M Xi","year":"2024","unstructured":"Xi M, Zhu J, Zhang F, Shen H, Chen J, Xiao Z, et al. Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads. Eur J Med Chem. 2024;276:116709.","journal-title":"Eur J Med Chem"},{"key":"2489_CR120","doi-asserted-by":"publisher","first-page":"1274088","DOI":"10.3389\/fphar.2023.1274088","volume":"14","author":"F Riccardi","year":"2023","unstructured":"Riccardi F, Dal Bo M, Macor P, Toffoli G. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front Pharmacol. 2023;14:1274088.","journal-title":"Front Pharmacol"},{"key":"2489_CR121","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255:232\u201340.","journal-title":"Cancer Lett"},{"key":"2489_CR122","doi-asserted-by":"crossref","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers (Basel). 2023;15:713.","DOI":"10.3390\/cancers15030713"},{"key":"2489_CR123","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"2489_CR124","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development. Cancer Discov. 2024;14:2089\u2013108.","journal-title":"Cancer Discov"},{"key":"2489_CR125","doi-asserted-by":"crossref","unstructured":"Okada R, Asakage T. Near-infrared photoimmunotherapy: basics and clinical application. Jpn J Clin Oncol. 2025;55:843-851.","DOI":"10.1093\/jjco\/hyaf069"},{"key":"2489_CR126","doi-asserted-by":"crossref","unstructured":"Buyukgolcigezli I, Tenekeci AK, Sahin IH. Opportunities and Challenges in Antibody-Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment. Cancers (Basel). 2025;17:958.","DOI":"10.3390\/cancers17060958"},{"key":"2489_CR127","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv Y, Cui X, Li T, Liu C, Wang A, Wang T, et al. Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin Exp Med. 2025;25:139.","journal-title":"Clin Exp Med"},{"key":"2489_CR128","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","volume":"24","author":"EY Jen","year":"2018","unstructured":"Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, et al. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia. Clin Cancer Res. 2018;24:3242\u20136.","journal-title":"Clin Cancer Res"},{"key":"2489_CR129","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490\u20136.","journal-title":"Clin Cancer Res"},{"key":"2489_CR130","volume":"17","author":"CSB Chia","year":"2022","unstructured":"Chia CSB. A Patent Review on FDA-Approved Antibody-Drug Conjugates. Their Linkers and Drug Payloads ChemMedChem. 2022;17:e202200032.","journal-title":"Their Linkers and Drug Payloads ChemMedChem"},{"key":"2489_CR131","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ptr.8407","volume":"39","author":"X Jiang","year":"2025","unstructured":"Jiang X, Nik Nabil WN, Ze Y, Dai R, Xi Z, Xu H. Unlocking natural potential: antibody-drug conjugates with naturally derived payloads for cancer therapy. Phytother Res. 2025;39:789\u2013874.","journal-title":"Phytother Res"},{"key":"2489_CR132","doi-asserted-by":"crossref","unstructured":"Salinas Y, Chauhan SC, Bandyopadhyay D. Small-Molecule Mitotic Inhibitors as Anticancer Agents: Discovery, Classification, Mechanisms of Action, and Clinical Trials. Int J Mol Sci. 2025;26:3279.","DOI":"10.3390\/ijms26073279"},{"key":"2489_CR133","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.22.02447","volume":"41","author":"P Narayan","year":"2023","unstructured":"Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, et al. US food and drug administration approval summary: Fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023;41:2108\u201316.","journal-title":"J Clin Oncol"},{"key":"2489_CR134","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/onco.13878","volume":"26","author":"LM Spring","year":"2021","unstructured":"Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021;26:827\u201334.","journal-title":"Oncologist"},{"key":"2489_CR135","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"2489_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar A, Sunildutt NP, Ahmed F, Soomro AM, Salih ARC, Parihar P, et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother. 2023;161:114408.","journal-title":"Biomed Pharmacother"},{"key":"2489_CR137","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazi\u00e8res J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241\u201351.","journal-title":"N Engl J Med"},{"key":"2489_CR138","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"key":"2489_CR139","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335.","journal-title":"N Engl J Med"},{"key":"2489_CR140","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/PPO.0000000000000626","volume":"28","author":"AC Johns","year":"2022","unstructured":"Johns AC, Campbell MT. Toxicities From Antibody-Drug Conjugates. Cancer J. 2022;28:469\u201378.","journal-title":"Cancer J"},{"key":"2489_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113","volume":"62","author":"A D'Arienzo","year":"2023","unstructured":"D\u2019Arienzo A, Verrazzo A, Pagliuca M, Napolitano F, Parola S, Viggiani M, et al. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine. 2023;62:102113.","journal-title":"EClinicalMedicine"},{"key":"2489_CR142","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.clbc.2024.04.003","volume":"24","author":"R Pedersini","year":"2024","unstructured":"Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, et al. Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metastatic breast cancer: a pooled analysis. Clin Breast Cancer. 2024;24:411\u201320.","journal-title":"Clin Breast Cancer"},{"key":"2489_CR143","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.urolonc.2021.10.002","volume":"41","author":"S Atiq","year":"2023","unstructured":"Atiq S, Hirshman N, Shariff A, Zhang T. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. Urol Oncol. 2023;41:410\u20139.","journal-title":"Urol Oncol"},{"key":"2489_CR144","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-025-00877-4","volume":"26","author":"Y Shi","year":"2025","unstructured":"Shi Y, Yao K, Zhao J, Yue Y, Wu H. Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database. BMC Pharmacol Toxicol. 2025;26:50.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2489_CR145","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10147-023-02414-x","volume":"28","author":"T Baba","year":"2023","unstructured":"Baba T, Kusumoto M, Kato T, Kurihara Y, Sasaki S, Oikado K, et al. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan. Int J Clin Oncol. 2023;28:1585\u201396.","journal-title":"Int J Clin Oncol"},{"key":"2489_CR146","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/DDDT.S508773","volume":"19","author":"D Liao","year":"2025","unstructured":"Liao D, Zhang J, Yan T, Chen Y, Fu Y, Xie N, et al. A systematic review of mechanisms, incidence, and management of Trastuzumab deruxtecan induced ILD\/pneumonitis in solid tumors. Drug Des Devel Ther. 2025;19:1655\u201368.","journal-title":"Drug Des Devel Ther"},{"key":"2489_CR147","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao LC, Wang JS, Ma X, Sodhi S, Ragusa JV, Liu B, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16:3167.","journal-title":"Nat Commun"},{"key":"2489_CR148","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022;8:98.","journal-title":"NPJ Breast Cancer"},{"key":"2489_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534","volume":"421","author":"RL Best","year":"2021","unstructured":"Best RL, LaPointe NE, Azarenko O, Miller H, Genualdi C, Chih S, et al. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol. 2021;421:115534.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2489_CR150","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","volume":"27","author":"ME Lacouture","year":"2022","unstructured":"Lacouture ME, Patel AB, Rosenberg JE, O\u2019Donnell PH. Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate Enfortumab Vedotin. Oncologist. 2022;27:e223\u201332.","journal-title":"Oncologist"},{"key":"2489_CR151","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","volume":"21","author":"W Bouleftour","year":"2022","unstructured":"Bouleftour W, Guillot A, Magne N. The anti-Nectin 4: a promising tumor cells target. A systematic review. Mol Cancer Ther. 2022;21:493\u2013501.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR152","doi-asserted-by":"crossref","unstructured":"Metrangolo V, Engelholm LH. Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers (Basel). 2024;16:447.","DOI":"10.3390\/cancers16020447"},{"key":"2489_CR153","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/acs.bioconjchem.3c00374","volume":"34","author":"JM Sasso","year":"2023","unstructured":"Sasso JM, Tenchov R, Bird R, Iyer KA, Ralhan K, Rodriguez Y, et al. The evolving landscape of antibody-drug conjugates. In depth analysis of recent research progress. Bioconjug Chem. 2023;34:1951\u20132000.","journal-title":"Bioconjug Chem"},{"key":"2489_CR154","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","volume":"34","author":"G Bogani","year":"2024","unstructured":"Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, et al. Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer. 2024;34:469\u201377.","journal-title":"Int J Gynecol Cancer"},{"key":"2489_CR155","doi-asserted-by":"publisher","first-page":"1039882","DOI":"10.3389\/fonc.2022.1039882","volume":"12","author":"P Yao","year":"2022","unstructured":"Yao P, Zhang Y, Zhang S, Wei X, Liu Y, Du C, et al. Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. Front Oncol. 2022;12:1039882.","journal-title":"Front Oncol"},{"key":"2489_CR156","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/JCO.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial. J Clin Oncol. 2023;41:5550\u201360.","journal-title":"J Clin Oncol"},{"key":"2489_CR157","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/JIPO-23-18","volume":"7","author":"K Feustel","year":"2024","unstructured":"Feustel K, Martin J, Falchook GS. B7\u2013H3 inhibitors in oncology clinical trials: a review. J Immunother Precis Oncol. 2024;7:53\u201366.","journal-title":"J Immunother Precis Oncol"},{"key":"2489_CR158","doi-asserted-by":"crossref","unstructured":"Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer. 2023;11:e007174.","DOI":"10.1136\/jitc-2023-007174"},{"key":"2489_CR159","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","volume":"26","author":"S Decary","year":"2020","unstructured":"Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, et al. Preclinical activity of SAR408701: a novel Anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res. 2020;26:6589\u201399.","journal-title":"Clin Cancer Res"},{"key":"2489_CR160","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2174\/0115680096260614231115192343","volume":"24","author":"KCA Cardenas","year":"2024","unstructured":"Cardenas KCA, Enos CW, Spear MR, Austin DE, Almofeez R, Kortchak S, et al. CT109-SN-38, a novel antibody-drug conjugate with dual specificity for CEACAM5 and 6, elicits potent killing of pancreatic cancer cells. Curr Cancer Drug Targets. 2024;24:720\u201332.","journal-title":"Curr Cancer Drug Targets"},{"key":"2489_CR161","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1158\/1538-7445.AM2025-2880","volume":"85","author":"M Xie","year":"2025","unstructured":"Xie M, Li P, Lu H, Dong S, Wilski N, Pandey P, et al. Abstract 2880: TM4SF1 as a novel target for different modalities (mAb, bispecific ADC, targeted siRNA) for the treatment of different solid tumor cancers. Cancer Res. 2025;85:2880\u20132880.","journal-title":"Cancer Res"},{"key":"2489_CR162","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/1535-7163.MCT-15-0188","volume":"14","author":"A Visintin","year":"2015","unstructured":"Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, et al. Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Mol Cancer Ther. 2015;14:1868\u201376.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR163","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/1078-0432.CCR-17-3795","volume":"24","author":"T Abrams","year":"2018","unstructured":"Abrams T, Connor A, Fanton C, Cohen SB, Huber T, Miller K, et al. Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors. Clin Cancer Res. 2018;24:4297\u2013308.","journal-title":"Clin Cancer Res"},{"key":"2489_CR164","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1158\/1538-7445.AM2024-3142","volume":"84","author":"C Kim","year":"2024","unstructured":"Kim C, Cho JG, Wi T, Moon J, Ko H-J, Lee J, et al. Abstract 3142: NN3201, a novel c-Kit targeting ADC, exhibits robust preclinical anti-tumor efficacy in SCLC and GIST models. Cancer Res. 2024;84:3142\u20133142.","journal-title":"Cancer Res"},{"key":"2489_CR165","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-23-1079","volume":"30","author":"SB Gitto","year":"2024","unstructured":"Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Xu H, et al. A B7-H4-targeting antibody-drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7\u2013H4 expression. Clin Cancer Res. 2024;30:1567\u201381.","journal-title":"Clin Cancer Res"},{"key":"2489_CR166","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-22-2630","volume":"29","author":"K Kinneer","year":"2023","unstructured":"Kinneer K, Wortmann P, Cooper ZA, Dickinson NJ, Masterson L, Cailleau T, et al. Design and preclinical evaluation of a novel B7-H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305. Clin Cancer Res. 2023;29:1086\u2013101.","journal-title":"Clin Cancer Res"},{"key":"2489_CR167","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74\u201389.","journal-title":"Cancer Discov"},{"key":"2489_CR168","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/2767-9764.CRC-23-0284","volume":"3","author":"J Tabernero","year":"2023","unstructured":"Tabernero J, Bedard PL, Bang YJ, Vieito M, Ryu MH, Fagniez N, et al. Tusamitamab ravtansine in patients with advanced solid tumors: phase I study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens. Cancer Res Commun. 2023;3:1662\u201371.","journal-title":"Cancer Res Commun"},{"key":"2489_CR169","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","volume":"33","author":"A Gazzah","year":"2022","unstructured":"Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022;33:416\u201325.","journal-title":"Ann Oncol"},{"issue":"19","key":"2489_CR170","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42(19):2281\u201394.","journal-title":"J Clin Oncol"},{"key":"2489_CR171","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","volume":"30","author":"RA Shatsky","year":"2024","unstructured":"Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024;30:3737\u201347.","journal-title":"Nat Med"},{"key":"2489_CR172","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","volume":"19","author":"JA Scribner","year":"2020","unstructured":"Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, et al. Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7\u2013H3 for solid cancer. Mol Cancer Ther. 2020;19:2235\u201344.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR173","doi-asserted-by":"crossref","unstructured":"Malapelle U, Parente P, Pepe F, Di Micco MC, Russo A, Clemente C, et al. B7-H3\/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? Int J Mol Sci. 2022;23:16077.","DOI":"10.3390\/ijms232416077"},{"key":"2489_CR174","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.24.00529","volume":"43","author":"N Turner","year":"2025","unstructured":"Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, et al. Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). J Clin Oncol. 2025;43:513\u201323.","journal-title":"J Clin Oncol"},{"key":"2489_CR175","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3636","volume":"42","author":"KPS Raghav","year":"2024","unstructured":"Raghav KPS, Hubert A, Fakih M, Fang H, Aristide MRN, Almeida CBd, et al. Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer. J Clin Oncol. 2024;42:TPS3636-TPS3636.","journal-title":"J Clin Oncol"},{"key":"2489_CR176","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25:901\u201311.","journal-title":"Lancet Oncol"},{"key":"2489_CR177","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","volume":"84","author":"ZZ Zhou","year":"2024","unstructured":"Zhou ZZ, Si Y, Zhang J, Chen K, George A, Kim S, et al. A dual-payload antibody-drug conjugate targeting CD276\/B7-H3 elicits cytotoxicity and immune activation in triple-negative breast cancer. Cancer Res. 2024;84:3848\u201363.","journal-title":"Cancer Res"},{"key":"2489_CR178","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202310318","volume":"63","author":"D Xiao","year":"2024","unstructured":"Xiao D, Liu L, Xie F, Dong J, Wang Y, Xu X, et al. Azobenzene-based linker strategy for selective activation of antibody-drug conjugates. Angew Chem Int Ed Engl. 2024;63:e202310318.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2489_CR179","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","volume":"8","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, et al. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 2021;8:e433\u201345.","journal-title":"Lancet Haematol"},{"key":"2489_CR180","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","volume":"25","author":"BS Kahl","year":"2019","unstructured":"Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, et al. A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2019;25:6986\u201394.","journal-title":"Clin Cancer Res"},{"key":"2489_CR181","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115986","volume":"132","author":"GP Collins","year":"2018","unstructured":"Collins GP, Horwitz SM, Davies A, Karnad A, Samaniego F, Spira AI, et al. Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based CD25-targeting antibody drug conjugate, in a phase 1 study of relapsed\/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma. Blood. 2018;132:1658.","journal-title":"Blood"},{"key":"2489_CR182","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12967-024-05985-z","volume":"23","author":"C Zhou","year":"2025","unstructured":"Zhou C, Wang B, Teng C, Yang H, Piha-Paul SA, Richardson G, et al. A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors. J Transl Med. 2025;23:37.","journal-title":"J Transl Med"},{"key":"2489_CR183","first-page":"22","volume":"7","author":"K Saleh","year":"2024","unstructured":"Saleh K, Khoury R, Khalife N, Chahine C, Ibrahim R, Tikriti Z, et al. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer. Cancer Drug Resist. 2024;7:22.","journal-title":"Cancer Drug Resist"},{"key":"2489_CR184","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.it.2024.12.006","volume":"46","author":"R Gupta","year":"2025","unstructured":"Gupta R, Kumar R, Penn CA, Wajapeyee N. Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments. Trends Immunol. 2025;46:166\u201381.","journal-title":"Trends Immunol"},{"key":"2489_CR185","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s12325-023-02729-1","volume":"41","author":"H Zhao","year":"2024","unstructured":"Zhao H, Xu Z, Li C, Xu T, Zhang J, Jiao J, et al. Efficacy and safety of Disitamab Vedotin combined with programmed death-1 inhibitor for advanced urothelial cancer: a case-series study. Adv Ther. 2024;41:857\u201366.","journal-title":"Adv Ther"},{"key":"2489_CR186","doi-asserted-by":"publisher","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","volume":"64","author":"L He","year":"2021","unstructured":"He L, Wang L, Wang Z, Li T, Chen H, Zhang Y, et al. Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy. J Med Chem. 2021;64:15716\u201326.","journal-title":"J Med Chem"},{"key":"2489_CR187","doi-asserted-by":"publisher","first-page":"1556245","DOI":"10.3389\/fphar.2025.1556245","volume":"16","author":"X Shi","year":"2025","unstructured":"Shi X, Tang K, Zhang Q, Han Q, Quan L, Li Y, et al. Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives. Front Pharmacol. 2025;16:1556245.","journal-title":"Front Pharmacol"},{"key":"2489_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101215","volume":"81","author":"S Dong","year":"2025","unstructured":"Dong S, Li X, Huang Q, Li Y, Li J, Zhu X, et al. Resistance to immunotherapy in non-small cell lung cancer: unraveling causes, developing effective strategies, and exploring potential breakthroughs. Drug Resist Updat. 2025;81:101215.","journal-title":"Drug Resist Updat"},{"key":"2489_CR189","doi-asserted-by":"publisher","first-page":"1535235","DOI":"10.3389\/fonc.2025.1535235","volume":"15","author":"G Wang","year":"2025","unstructured":"Wang G, Yang H, Wang Y, Qin J. Ovarian cancer targeted therapy: current landscape and future challenges. Front Oncol. 2025;15:1535235.","journal-title":"Front Oncol"},{"key":"2489_CR190","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11523-025-01140-w","volume":"20","author":"G Lalli","year":"2025","unstructured":"Lalli G, Sabatucci I, Paderno M, Martinelli F, Signorelli M, Maruccio M, et al. Navigating the landscape of resistance mechanisms in antibody-drug conjugates for cancer treatment. Target Oncol. 2025;20:419\u201330.","journal-title":"Target Oncol"},{"key":"2489_CR191","doi-asserted-by":"crossref","unstructured":"Jose J, Hooper JD, Souza-Fonseca-Guimaraes F. Highlights of 2024. Broadening anti-cancer immunotherapy modalities with antibody-drug conjugates: emerging insights from clinical studies. Immunol Cell Biol. 2025;103:530-534.","DOI":"10.1111\/imcb.70017"},{"key":"2489_CR192","doi-asserted-by":"crossref","unstructured":"Tahayneh K, Idkedek M, Abu Akar F. NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives. J Clin Med. 2025;14:1025.","DOI":"10.3390\/jcm14031025"},{"key":"2489_CR193","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.7150\/ijbs.105973","volume":"21","author":"W Ouyang","year":"2025","unstructured":"Ouyang W, Xu Z, Guan S, Hu Y, Gou X, Liu Z, et al. Advancement opportunities and endeavor of innovative targeted therapies for small cell lung cancer. Int J Biol Sci. 2025;21:1322\u201341.","journal-title":"Int J Biol Sci"},{"key":"2489_CR194","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002302","volume":"6","author":"EI Bragasin","year":"2025","unstructured":"Bragasin EI, Cheng J, Ford L, Poei D, Ali S, Hsu R. Advances in adoptive cell therapies in small cell lung cancer. Exploration of Targeted Anti-tumor Therapy. 2025;6:1002302.","journal-title":"Exploration of Targeted Anti-tumor Therapy"},{"key":"2489_CR195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1017400","volume":"13","author":"D Xie","year":"2022","unstructured":"Xie D, Wang Q, Wu G. Research progress in inducing immunogenic cell death of tumor cells. Front Immunol. 2022;13:1017400.","journal-title":"Front Immunol"},{"key":"2489_CR196","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2220466","volume":"15","author":"X Tan","year":"2023","unstructured":"Tan X, Fang P, Li K, You M, Cao Y, Xu H, et al. A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells. MAbs. 2023;15:2220466.","journal-title":"MAbs"},{"key":"2489_CR197","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P M\u00fcller","year":"2014","unstructured":"M\u00fcller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2:741\u201355.","journal-title":"Cancer Immunol Res"},{"key":"2489_CR198","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/jcmm.14356","volume":"23","author":"J Zhou","year":"2019","unstructured":"Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23:4854\u201365.","journal-title":"J Cell Mol Med"},{"key":"2489_CR199","doi-asserted-by":"crossref","unstructured":"Schmid P, Loi S, De la Cruz Merino L, Yerushalmi R, Im SA, Sonnenblick A, et al. 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC). ESMO Open. 2024;9:109203","DOI":"10.1016\/j.esmoop.2024.103203"},{"key":"2489_CR200","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1038\/s41467-024-49932-4","volume":"15","author":"N Malli Cetinbas","year":"2024","unstructured":"Malli Cetinbas N, Monnell T, Soomer-James J, Shaw P, Lancaster K, Catcott KC, et al. Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses. Nat Commun. 2024;15:5842.","journal-title":"Nat Commun"},{"key":"2489_CR201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1516419","volume":"16","author":"R Long","year":"2025","unstructured":"Long R, Zuo H, Tang G, Zhang C, Yue X, Yang J, et al. Antibody-drug conjugates in cancer therapy: applications and future advances. Front Immunol. 2025;16:1516419.","journal-title":"Front Immunol"},{"key":"2489_CR202","doi-asserted-by":"crossref","unstructured":"Bhatnagar S, Revuri V, Shah M, Larson P, Shao Z, Yu D, et al. Combination of STING and TLR 7\/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy. Cancers (Basel). 2022;14:6091.","DOI":"10.3390\/cancers14246091"},{"issue":"5","key":"2489_CR203","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.22.00739","volume":"41","author":"DR Camidge","year":"2023","unstructured":"Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer. J Clin Oncol. 2023;41(5):1105\u201315.","journal-title":"J Clin Oncol"},{"key":"2489_CR204","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.21037\/tlcr-23-288","volume":"12","author":"L Kujtan","year":"2023","unstructured":"Kujtan L, Subramanian J. Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? Transl Lung Cancer Res. 2023;12:1826\u20139.","journal-title":"Transl Lung Cancer Res"},{"key":"2489_CR205","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388.","journal-title":"N Engl J Med"},{"key":"2489_CR206","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/ajhp\/zxab464","volume":"79","author":"KS Hanna","year":"2022","unstructured":"Hanna KS, Larson S, Nguyen J, Boudreau J, Bulin J, Rolf M. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer. Am J Health-Syst Pharm. 2022;79:629\u201335.","journal-title":"Am J Health-Syst Pharm"},{"key":"2489_CR207","doi-asserted-by":"crossref","unstructured":"Fu R, Wang C, Yin T, Zhang X, Xu Y, Shi Y, et al. A novel and promising therapeutic approach for treating pancreatic cancer: Nectin\u20114\u2011targeted antibody\u2011drug conjugates alone or combined with autophagy inhibitors. Int J Mol Med. 2025;55:66.","DOI":"10.3892\/ijmm.2025.5507"},{"key":"2489_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06665-y","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Nan Y, Ma C, Lu X, Wang Q, Huang X, et al. A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE. Cell Death Dis. 2024;15:293.","journal-title":"Cell Death Dis"},{"key":"2489_CR209","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown JS, O\u2019Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017;7:20\u201337.","journal-title":"Cancer Discov"},{"key":"2489_CR210","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-16-2401","volume":"23","author":"TM Cardillo","year":"2017","unstructured":"Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1\/2-wild-type Triple-Negative Breast Cancer. Clin Cancer Res. 2017;23:3405\u201315.","journal-title":"Clin Cancer Res"},{"key":"2489_CR211","first-page":"161","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Li L, Fu H, Yao Q, Wang L, Lou L. Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers. Am J Cancer Res. 2023;13:161\u201375.","journal-title":"Am J Cancer Res"},{"key":"2489_CR212","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","volume":"17","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, et al. IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML. Mol Cancer Ther. 2018;17:1271\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR213","doi-asserted-by":"crossref","unstructured":"Ghelli Luserna di Ror\u00e0 A, Jandoubi M, Padella A, Ferrari A, Marranci A, Mazzotti C, et al. Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. J Transl Med. 2024;22:1062.","DOI":"10.1186\/s12967-024-05838-9"},{"key":"2489_CR214","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, Li P, Yang T, Zhu J, Sun L, Zhang Z, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17:1.","journal-title":"J Hematol Oncol"},{"key":"2489_CR215","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209.","journal-title":"Breast Cancer Res"},{"key":"2489_CR216","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","volume":"181","author":"PA Trail","year":"2018","unstructured":"Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018;181:126\u201342.","journal-title":"Pharmacol Ther"},{"key":"2489_CR217","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","volume":"18","author":"JF Ponte","year":"2016","unstructured":"Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia. 2016;18:775\u201384.","journal-title":"Neoplasia"},{"key":"2489_CR218","doi-asserted-by":"publisher","first-page":"10211","DOI":"10.3390\/curroncol30120743","volume":"30","author":"MA Fenton","year":"2023","unstructured":"Fenton MA, Tarantino P, Graff SL. Sequencing antibody drug conjugates in breast cancer: exploring future roles. Curr Oncol. 2023;30:10211\u201323.","journal-title":"Curr Oncol"},{"key":"2489_CR219","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/0008-5472.CAN-12-0600","volume":"72","author":"DM Rommelfanger","year":"2012","unstructured":"Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res. 2012;72:4753\u201364.","journal-title":"Cancer Res"},{"key":"2489_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109248","volume":"27","author":"MP Gon\u00e7alves","year":"2024","unstructured":"Gon\u00e7alves MP, Farah R, Bikorimana JP, Abusarah J, El-Hachem N, Saad W, et al. A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses. iScience. 2024;27:109248.","journal-title":"iScience"},{"key":"2489_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51498-0","volume":"15","author":"Z Taha","year":"2024","unstructured":"Taha Z, Crupi MJF, Alluqmani N, MacKenzie D, Vallati S, Whelan JT, et al. Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy. Nat Commun. 2024;15:7267.","journal-title":"Nat Commun"},{"key":"2489_CR222","doi-asserted-by":"crossref","unstructured":"Palma M. Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges. Vaccines (Basel). 2025;13:344.","DOI":"10.3390\/vaccines13040344"},{"key":"2489_CR223","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/CM9.0000000000001932","volume":"135","author":"L Li","year":"2021","unstructured":"Li L, Zhang D, Liu B, Lv D, Zhai J, Guan X, et al. Antibody-drug conjugates in HER2-positive breast cancer. Chin Med J (Engl). 2021;135:261\u20137.","journal-title":"Chin Med J (Engl)"},{"key":"2489_CR224","doi-asserted-by":"crossref","unstructured":"Jiang Y, Dong S, Wang Y. Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism. Cancers (Basel). 2025;17:496.","DOI":"10.3390\/cancers17030496"},{"key":"2489_CR225","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2024-202866","volume":"144","author":"L Song","year":"2024","unstructured":"Song L, Qi J, Wang Z, Li X, Xiao S, Zhu H, et al. BL-M11D1, a novel CD33 antibody-drug conjugate (ADC), in patients with relapsed\/ refractory acute myeloid leukemia: initial results from first-in-human phase 1 study. Blood. 2024;144:4260.","journal-title":"Blood"},{"key":"2489_CR226","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329\u201340.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR227","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41557-024-01507-y","volume":"16","author":"T Journeaux","year":"2024","unstructured":"Journeaux T, Bernardes GJL. Homogeneous multi-payload antibody-drug conjugates. Nat Chem. 2024;16:854\u201370.","journal-title":"Nat Chem"},{"key":"2489_CR228","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-025-02265-2","volume":"24","author":"Y Pan","year":"2025","unstructured":"Pan Y, Yuan C, Zeng C, Sun C, Xia L, Wang G, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025;24:52.","journal-title":"Mol Cancer"},{"key":"2489_CR229","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00262-021-03097-x","volume":"71","author":"C Liu","year":"2022","unstructured":"Liu C, Zhang G, Xiang K, Kim Y, Lavoie RR, Lucien F, et al. Targeting the immune checkpoint B7\u2013H3 for next-generation cancer immunotherapy. Cancer Immunol Immunother. 2022;71:1549\u201367.","journal-title":"Cancer Immunol Immunother"},{"key":"2489_CR230","doi-asserted-by":"publisher","unstructured":"Wang X, Zhao L, Gao F, Meng Y, Yang J, Zhu M, et al. HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials. Curr Med Chem. 2025. https:\/\/doi.org\/10.2174\/0109298673358929250213093803","DOI":"10.2174\/0109298673358929250213093803"},{"key":"2489_CR231","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1158\/1538-7445.AM2025-2503","volume":"85","author":"M Choi","year":"2025","unstructured":"Choi M, Bae S, Lee D, Choi H. Abstract 2503: analytic platform for optimal target pair selection in bispecific antibody-drug conjugates using scRNA-seq and spatial transcriptomics data. Cancer Res. 2025;85:2503\u20132503.","journal-title":"Cancer Res"},{"key":"2489_CR232","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1016\/j.apsb.2022.08.022","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, et al. New opportunities and challenges of natural products research: when target identification meets single-cell multiomics. Acta Pharm Sin B. 2022;12:4011\u201339.","journal-title":"Acta Pharm Sin B"},{"key":"2489_CR233","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/00498254.2024.2352051","volume":"54","author":"ME Gray","year":"2024","unstructured":"Gray ME, Zielinski KM, Xu F, Elder KK, McKay SJ, Ojo VT, et al. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers. Xenobiotica. 2024;54:458\u201368.","journal-title":"Xenobiotica"},{"key":"2489_CR234","doi-asserted-by":"crossref","unstructured":"Sheyi R, de la Torre BG, Albericio F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics. 2022;14:396.","DOI":"10.3390\/pharmaceutics14020396"},{"key":"2489_CR235","doi-asserted-by":"publisher","first-page":"18124","DOI":"10.1021\/acs.jmedchem.4c01251","volume":"67","author":"T Watanabe","year":"2024","unstructured":"Watanabe T, Arashida N, Fujii T, Shikida N, Ito K, Shimbo K, et al. Exo-cleavable linkers: enhanced stability and therapeutic efficacy in antibody-drug conjugates. J Med Chem. 2024;67:18124\u201338.","journal-title":"J Med Chem"},{"key":"2489_CR236","volume":"26","author":"U Majumder","year":"2025","unstructured":"Majumder U, Zhu X, Custar D, Li D, Fang H, McGonigle S, et al. A Novel Concept for Cleavable Linkers Applicable to Conjugation Chemistry - Design. Synthesis and Characterization Chembiochem. 2025;26:e202400826.","journal-title":"Synthesis and Characterization Chembiochem"},{"key":"2489_CR237","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11095-023-03649-z","volume":"41","author":"M Li","year":"2024","unstructured":"Li M, Zhao X, Yu C, Wang L. Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy. Pharm Res. 2024;41:419\u201340.","journal-title":"Pharm Res"},{"key":"2489_CR238","doi-asserted-by":"publisher","DOI":"10.1007\/s41061-025-00497-w","volume":"383","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yang Z, Liu Y, Liu Y, Qu J, Pan X. Recent advances in smart linkage strategies for developing drug conjugates for targeted delivery. Top Curr Chem. 2025;383:13.","journal-title":"Top Curr Chem"},{"key":"2489_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102902","volume":"134","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, et al. Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target. Cancer Treat Rev. 2025;134:102902.","journal-title":"Cancer Treat Rev"},{"key":"2489_CR240","first-page":"728","volume":"34","author":"T Fujii","year":"2023","unstructured":"Fujii T, Matsuda Y, Seki T, Shikida N, Iwai Y, Ooba Y, et al. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production. Bioconjug Chem. 2023;34:728\u201338.","journal-title":"Bioconjug Chem"},{"key":"2489_CR241","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1021\/acs.molpharmaceut.1c00473","volume":"18","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Seki T, Yamada K, Ooba Y, Takahashi K, Fujii T, et al. Chemical site-specific conjugation platform to improve the pharmacokinetics and therapeutic index of antibody-drug conjugates. Mol Pharm. 2021;18:4058\u201366.","journal-title":"Mol Pharm"},{"key":"2489_CR242","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14712598.2024.2305266","volume":"24","author":"DV Hingorani","year":"2024","unstructured":"Hingorani DV. An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio. Expert Opin Biol Ther. 2024;24:31\u20136.","journal-title":"Expert Opin Biol Ther"},{"key":"2489_CR243","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/acs.bioconjchem.4c00392","volume":"36","author":"J Long","year":"2025","unstructured":"Long J, Shao T, Wang Y, Chen T, Chen Y, Chen YL, et al. Pegylation of dipeptide linker improves therapeutic index and pharmacokinetics of antibody-drug conjugates. Bioconjug Chem. 2025;36:179\u201389.","journal-title":"Bioconjug Chem"},{"key":"2489_CR244","doi-asserted-by":"publisher","first-page":"19852","DOI":"10.1021\/acs.jmedchem.4c02243","volume":"67","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang L, Cao X, Song R, Yin S, Cheng Z, et al. Evaluation of double self-immolative linker-based antibody-drug conjugate FDA022-BB05 with enhanced therapeutic potential. J Med Chem. 2024;67:19852\u201373.","journal-title":"J Med Chem"},{"key":"2489_CR245","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","volume":"144","author":"RP Taylor","year":"2024","unstructured":"Taylor RP, Lindorfer MA. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms. Blood. 2024;144:137\u201344.","journal-title":"Blood"},{"key":"2489_CR246","doi-asserted-by":"crossref","unstructured":"Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired Resistance to Antibody-Drug Conjugates. Cancers (Basel). 2019;11:394.","DOI":"10.3390\/cancers11030394"},{"key":"2489_CR247","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15:2825\u201334.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR248","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00210-021-02112-3","volume":"394","author":"D Theile","year":"2021","unstructured":"Theile D, Wizgall P. Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection? Naunyn Schmiedebergs Arch Pharmacol. 2021;394:1621\u201332.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2489_CR249","doi-asserted-by":"publisher","first-page":"235237352513178","DOI":"10.1177\/23523735251317865","volume":"11","author":"S Ps","year":"2025","unstructured":"Ps S. Zhou Y, Stelter I, Hanlon T, Bekele RT, Bellmunt J, Szallasi Z, Mouw KW: Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer. Bladder Cancer. 2025;11:23523735251317864.","journal-title":"Bladder Cancer"},{"key":"2489_CR250","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1538-7445.AM2015-1680","volume":"75","author":"MJ Meyer","year":"2015","unstructured":"Meyer MJ, Jenkins D, Batt D, Mosher R, Isaacs R, Hu T, et al. Abstract 1680: in vitro and in vivo activity of a highly potent and novel FGFR2\/FGFR4 dual targeting antibody-drug conjugate. Cancer Res. 2015;75:1680\u20131680.","journal-title":"Cancer Res"},{"key":"2489_CR251","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/14728222.2022.2077188","volume":"26","author":"X Xie","year":"2022","unstructured":"Xie X, Lee J, Iwase T, Kai M, Ueno NT. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opin Ther Targets. 2022;26:405\u201325.","journal-title":"Expert Opin Ther Targets"},{"key":"2489_CR252","doi-asserted-by":"crossref","unstructured":"Xie X, Lee J, Fuson JA, Liu H, Iwase T, Yun K, et al. Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. Biomedicines. 2023;11:735.","DOI":"10.3390\/biomedicines11030735"},{"key":"2489_CR253","doi-asserted-by":"crossref","unstructured":"Shi Y, Bashian EE, Hou Y, Wu P. Chemical immunology: Recent advances in tool development and applications. Cell Chem Biol. 2024.","DOI":"10.1016\/j.chembiol.2024.02.006"},{"key":"2489_CR254","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9:175.","journal-title":"Signal Transduct Target Ther"},{"key":"2489_CR255","doi-asserted-by":"publisher","first-page":"15756","DOI":"10.1021\/acs.jmedchem.4c01384","volume":"67","author":"AM Patel","year":"2024","unstructured":"Patel AM, Willingham A, Cheng AC, Tomazela D, Bowman E, Kofman E, et al. Design and optimization of selectivity-tunable Toll-like receptor 7\/8 agonists as novel antibody-drug conjugate payloads. J Med Chem. 2024;67:15756\u201379.","journal-title":"J Med Chem"},{"key":"2489_CR256","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14656566.2025.2493892","volume":"26","author":"M Ocker","year":"2025","unstructured":"Ocker M, Mayr C, Huber-Cantonati P, Kiesslich T, Neureiter D. New frontiers in the pharmacological management of biliary tract carcinomas: the emerging role of drug conjugates. Expert Opin Pharmacother. 2025;26:887\u201396.","journal-title":"Expert Opin Pharmacother"},{"key":"2489_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108371","volume":"244","author":"H Zhu","year":"2023","unstructured":"Zhu H, Wang J, Zhang Q, Pan X, Zhang J. Novel strategies and promising opportunities for targeted protein degradation: an innovative therapeutic approach to overcome cancer resistance. Pharmacol Ther. 2023;244:108371.","journal-title":"Pharmacol Ther"},{"key":"2489_CR258","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41419-024-06837-w","volume":"15","author":"P Yu","year":"2024","unstructured":"Yu P, Zhu C, You X, Gu W, Wang X, Wang Y, et al. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies. Cell Death Dis. 2024;15:433.","journal-title":"Cell Death Dis"},{"key":"2489_CR259","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","volume":"35","author":"S Peters","year":"2024","unstructured":"Peters S, Loi S, Andr\u00e9 F, Chandarlapaty S, Felip E, Finn SP, et al. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation. Ann Oncol. 2024;35:607\u201329.","journal-title":"Ann Oncol"},{"key":"2489_CR260","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41523-025-00743-w","volume":"11","author":"AA Davis","year":"2025","unstructured":"Davis AA, Hesse J, Pereira PMR, Ma CX. Novel treatment approaches utilizing antibody-drug conjugates in breast cancer. NPJ Breast Cancer. 2025;11:42.","journal-title":"NPJ Breast Cancer"},{"key":"2489_CR261","doi-asserted-by":"crossref","unstructured":"Afzal MZ, Vahdat LT. Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine. J Pers Med. 2024;14:719.","DOI":"10.3390\/jpm14070719"},{"key":"2489_CR262","doi-asserted-by":"crossref","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers (Basel). 2024;16:2478.","DOI":"10.3390\/cancers16132478"},{"key":"2489_CR263","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"2489_CR264","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380.","journal-title":"Science"},{"key":"2489_CR265","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","volume":"39","author":"L Zitvogel","year":"2013","unstructured":"Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74\u201388.","journal-title":"Immunity"},{"key":"2489_CR266","doi-asserted-by":"crossref","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. 2023;133:e172156.","DOI":"10.1172\/JCI172156"},{"key":"2489_CR267","doi-asserted-by":"crossref","unstructured":"Wittwer NL, Staudacher AH, Liapis V, Cardarelli P, Warren H, Brown MP. An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. J Immunother Cancer. 2023;11:e006274.","DOI":"10.1136\/jitc-2022-006274"},{"key":"2489_CR268","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1535-7163.MCT-23-0315","volume":"22","author":"B Valsasina","year":"2023","unstructured":"Valsasina B, Orsini P, Caruso M, Albanese C, Ciavolella A, Cucchi U, et al. Novel Thienoduocarmycin-Trastuzumab ADC demonstrates strong antitumor efficacy with favorable safety profile in preclinical studies. Mol Cancer Ther. 2023;22:1465\u201378.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR269","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.07.003","volume":"154\u2013155","author":"Y Matsumura","year":"2020","unstructured":"Matsumura Y. Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Adv Drug Deliv Rev. 2020;154\u2013155:142\u201350.","journal-title":"Adv Drug Deliv Rev"},{"key":"2489_CR270","doi-asserted-by":"crossref","unstructured":"Al Sbihi A, Alasfour M, Pongas G. Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma. Cancers (Basel). 2024;16:827.","DOI":"10.3390\/cancers16040827"},{"key":"2489_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102393","volume":"106","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Nagasaka M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022;106:102393.","journal-title":"Cancer Treat Rev"},{"key":"2489_CR272","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10928-023-09884-6","volume":"51","author":"B Scheuher","year":"2024","unstructured":"Scheuher B, Ghusinga KR, McGirr K, Nowak M, Panday S, Apgar J, et al. Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs). J Pharmacokinet Pharmacodyn. 2024;51:429\u201347.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2489_CR273","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","volume":"31","author":"PM Drake","year":"2017","unstructured":"Drake PM, Rabuka D. Recent developments in ADC technology: preclinical studies signal future clinical trends. BioDrugs. 2017;31:521\u201331.","journal-title":"BioDrugs"},{"key":"2489_CR274","doi-asserted-by":"crossref","unstructured":"Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, et al. Factors Affecting the Pharmacology of Antibody-Drug Conjugates. Antibodies (Basel). 2018;7:10.","DOI":"10.3390\/antib7010010"},{"key":"2489_CR275","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1158\/1535-7163.MCT-19-0993","volume":"19","author":"M Williams","year":"2020","unstructured":"Williams M, Spreafico A, Vashisht K, Hinrichs MJ. Patient selection strategies to maximize therapeutic index of antibody-drug conjugates: prior approaches and future directions. Mol Cancer Ther. 2020;19:1770\u201383.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR276","doi-asserted-by":"crossref","unstructured":"Asiimwe IG, Chtiba N, Mouksassi S, Pillai GC, Peter RM, Yuen E, et al. Postmarketing Assessment of Antibody-Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach. CPT Pharmacometrics Syst Pharmacol. 2025.","DOI":"10.1002\/psp4.70013"},{"key":"2489_CR277","doi-asserted-by":"crossref","unstructured":"Leleu X, Bobin A, Herbelin A, Gombert JM, Rajkumar SV. Time for a paradigm shift in immunotherapy-based BCMA\/CD3 bispecific drug development in multiple myeloma. Leukemia. 2025;39:1593-1594.","DOI":"10.1038\/s41375-025-02610-w"},{"key":"2489_CR278","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1158\/1538-7445.AM2025-4338","volume":"85","author":"Y Wang","year":"2025","unstructured":"Wang Y, Gao X, Dan M, Hui X, Yao B, Zhang Y, et al. Abstract 4338: SYS6042, a novel anti-TROP2 pH-sensitive antibody-drug conjugate (ADC) with improved therapeutic window. Cancer Res. 2025;85:4338\u20134338.","journal-title":"Cancer Res"},{"key":"2489_CR279","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20:558\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"2489_CR280","doi-asserted-by":"crossref","unstructured":"Gong J, Zhang W, Balthasar JP. Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index. Cancers (Basel). 2025;17:1032.","DOI":"10.3390\/cancers17061032"},{"key":"2489_CR281","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736\u201342.","journal-title":"Br J Cancer"},{"key":"2489_CR282","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24:809\u201317.","journal-title":"Curr Oncol Rep"},{"key":"2489_CR283","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00667-y","volume":"14","author":"R Ran","year":"2025","unstructured":"Ran R, Chen X, Yang J, Xu B. Immunotherapy in breast cancer: current landscape and emerging trends. Exp Hematol Oncol. 2025;14:77.","journal-title":"Exp Hematol Oncol"},{"key":"2489_CR284","doi-asserted-by":"crossref","unstructured":"Stumpo S, Carlini A, Mantuano F, Di Federico A, Melotti B, Sperandi F, et al. Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data. Cancers (Basel). 2025;17:1750.","DOI":"10.3390\/cancers17111750"},{"key":"2489_CR285","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","volume":"17","author":"JR McCombs","year":"2015","unstructured":"McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17:339\u201351.","journal-title":"AAPS J"},{"key":"2489_CR286","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00373","volume":"10","author":"H Tang","year":"2019","unstructured":"Tang H, Liu Y, Yu Z, Sun M, Lin L, Liu W, et al. The analysis of key factors related to ADCs structural design. Front Pharmacol. 2019;10:373.","journal-title":"Front Pharmacol"},{"key":"2489_CR287","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36:121\u201335.","journal-title":"Invest New Drugs"},{"key":"2489_CR288","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-62703-541-5_11","volume":"1045","author":"S Bhakta","year":"2013","unstructured":"Bhakta S, Raab H, Junutula JR. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers. Methods Mol Biol. 2013;1045:189\u2013203.","journal-title":"Methods Mol Biol"},{"key":"2489_CR289","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1039\/D1SC05243H","volume":"13","author":"N Zacharias","year":"2022","unstructured":"Zacharias N, Podust VN, Kajihara KK, Leipold D, Del Rosario G, Thayer D, et al. A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chem Sci. 2022;13:3147\u201360.","journal-title":"Chem Sci"},{"key":"2489_CR290","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/bc400574z","volume":"25","author":"P Dennler","year":"2014","unstructured":"Dennler P, Chiotellis A, Fischer E, Br\u00e9geon D, Belmant C, Gauthier L, et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem. 2014;25:569\u201378.","journal-title":"Bioconjug Chem"},{"key":"2489_CR291","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp A, Hofsess S, Cardillo TM, Govindan SV, Donnell J, Thurber GM. Antibody-drug conjugate Sacituzumab Govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol Cancer Ther. 2023;22:102\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR292","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.130085","volume":"118","author":"GR Mathi","year":"2025","unstructured":"Mathi GR, Lee BS, Chun Y, Shin S, Kweon S, Go A, et al. Design, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy. Bioorg Med Chem Lett. 2025;118:130085.","journal-title":"Bioorg Med Chem Lett"},{"key":"2489_CR293","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.molonc.2014.09.011","volume":"9","author":"DV Catenacci","year":"2015","unstructured":"Catenacci DV. Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967\u201396.","journal-title":"Mol Oncol"},{"key":"2489_CR294","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66.","journal-title":"Nat Rev Dis Primers"},{"key":"2489_CR295","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391.","journal-title":"N Engl J Med"},{"key":"2489_CR296","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","volume":"21","author":"KS Saini","year":"2021","unstructured":"Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther. 2021;21:945\u201362.","journal-title":"Expert Opin Biol Ther"},{"key":"2489_CR297","doi-asserted-by":"crossref","unstructured":"Gilad Y, Gellerman G, Lonard DM, O'Malley BW. Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations. Cancers (Basel). 2021;13:669.","DOI":"10.3390\/cancers13040669"},{"key":"2489_CR298","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25\u201339.","journal-title":"Nat Rev Immunol"},{"key":"2489_CR299","first-page":"53","volume":"1805","author":"AD Garg","year":"2010","unstructured":"Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010;1805:53\u201371.","journal-title":"Biochim Biophys Acta"},{"key":"2489_CR300","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17:e0264138.","journal-title":"PLoS ONE"},{"key":"2489_CR301","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins CJ, Bates KM, Rimm DL. HER2 testing: evolution and update for a companion diagnostic assay. Nat Rev Clin Oncol. 2025;22:408\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"2489_CR302","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1535370217740861","volume":"243","author":"KB Goldberg","year":"2018","unstructured":"Goldberg KB, Blumenthal GM, McKee AE, Pazdur R. The FDA Oncology Center of Excellence and precision medicine. Exp Biol Med (Maywood). 2018;243:308\u201312.","journal-title":"Exp Biol Med (Maywood)"},{"key":"2489_CR303","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","volume":"25","author":"S Coats","year":"2019","unstructured":"Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yao NS, et al. Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019;25:5441\u20138.","journal-title":"Clin Cancer Res"},{"key":"2489_CR304","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J R\u00fcschoff","year":"2012","unstructured":"R\u00fcschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637\u201350.","journal-title":"Mod Pathol"},{"issue":"Suppl 6","key":"2489_CR305","doi-asserted-by":"publisher","first-page":"vi19","DOI":"10.1093\/annonc\/mds190","volume":"23","author":"F Penault-Llorca","year":"2012","unstructured":"Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012;23(Suppl 6):vi19-22.","journal-title":"Ann Oncol"},{"key":"2489_CR306","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.1211","volume":"106","author":"IH Bartelink","year":"2019","unstructured":"Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, et al. Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clin Pharmacol Ther. 2019;106:148\u201363.","journal-title":"Clin Pharmacol Ther"},{"key":"2489_CR307","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718590","volume":"11","author":"S Parakh","year":"2021","unstructured":"Parakh S, Nicolazzo J, Scott AM, Gan HK. Antibody drug conjugates in glioblastoma - is there a future for them? Front Oncol. 2021;11:718590.","journal-title":"Front Oncol"},{"key":"2489_CR308","doi-asserted-by":"crossref","unstructured":"Guzzeloni V, Veschini L, Pedica F, Ferrero E, Ferrarini M. 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. Antibodies (Basel). 2022;11:46.","DOI":"10.3390\/antib11030046"},{"key":"2489_CR309","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/14712598.2023.2282729","volume":"23","author":"HK Gan","year":"2023","unstructured":"Gan HK, Parakh S, Osellame LD, Cher L, Uccellini A, Hafeez U, et al. Antibody drug conjugates for glioblastoma: current progress towards clinical use. Expert Opin Biol Ther. 2023;23:1089\u2013102.","journal-title":"Expert Opin Biol Ther"},{"key":"2489_CR310","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024;21:675\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"key":"2489_CR311","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43324-w","volume":"14","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat Commun. 2023;14:7496.","journal-title":"Nat Commun"},{"key":"2489_CR312","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1535-7163.MCT-20-0526","volume":"20","author":"RD Lyski","year":"2021","unstructured":"Lyski RD, Bou LB, Lau UY, Meyer DW, Cochran JH, Okeley NM, et al. Development of novel antibody-camptothecin conjugates. Mol Cancer Ther. 2021;20:329\u201339.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR313","doi-asserted-by":"crossref","unstructured":"Belluomini L, Sposito M, Avancini A, Insolda J, Milella M, Rossi A, et al. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers (Basel). 2023;15:5368.","DOI":"10.3390\/cancers15225368"},{"key":"2489_CR314","first-page":"18","volume":"59","author":"GA Van Dongen","year":"2015","unstructured":"Van Dongen GA, Huisman MC, Boellaard R, Harry Hendrikse N, Windhorst AD, Visser GW, et al. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? Q J Nucl Med Mol Imaging. 2015;59:18\u201338.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2489_CR315","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.7150\/thno.32883","volume":"9","author":"LK Kristensen","year":"2019","unstructured":"Kristensen LK, Christensen C, Jensen MM, Agnew BJ, Schj\u00f6th-Frydendahl C, Kjaer A, et al. Site-specifically labeled (89)Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model. Theranostics. 2019;9:4409\u201320.","journal-title":"Theranostics"},{"key":"2489_CR316","doi-asserted-by":"crossref","unstructured":"Ma D, Dai LJ, Wu XR, Liu CL, Zhao S, Zhang H, Chen L, Xiao Y, Li M, Zhao YZ, et al: Spatial determinants of antibody-drug conjugate SHRA1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell 2025, 43:1061\u20131075.e1067.","DOI":"10.1016\/j.ccell.2025.03.017"},{"key":"2489_CR317","doi-asserted-by":"crossref","unstructured":"Massa D, Tosi A, Rosato A, Guarneri V, Dieci MV. Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. Cancers (Basel). 2022;14:4885.","DOI":"10.3390\/cancers14194885"},{"key":"2489_CR318","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2229101","volume":"15","author":"H Maecker","year":"2023","unstructured":"Maecker H, Jonnalagadda V, Bhakta S, Jammalamadaka V, Junutula JR. Exploration of the antibody-drug conjugate clinical landscape. MAbs. 2023;15:2229101.","journal-title":"MAbs"},{"key":"2489_CR319","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","volume":"29","author":"Y Pommier","year":"2023","unstructured":"Pommier Y, Thomas A. New life of Topoisomerase I inhibitors as antibody-drug conjugate warheads. Clin Cancer Res. 2023;29:991\u20133.","journal-title":"Clin Cancer Res"},{"key":"2489_CR320","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s11912-024-01582-x","volume":"26","author":"A Bhushan","year":"2024","unstructured":"Bhushan A, Misra P. Economics of antibody drug conjugates (ADCs): innovation, investment and market dynamics. Curr Oncol Rep. 2024;26:1224\u201335.","journal-title":"Curr Oncol Rep"},{"key":"2489_CR321","doi-asserted-by":"publisher","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","volume":"17","author":"S Crescioli","year":"2025","unstructured":"Crescioli S, Kaplon H, Wang L, Visweswaraiah J, Kapoor V, Reichert JM. Antibodies to watch in 2025. MAbs. 2025;17:2443538.","journal-title":"MAbs"},{"key":"2489_CR322","doi-asserted-by":"crossref","unstructured":"Kiss B, Borb\u00e9ly J. Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment. Pharmaceutics. 2023;15:1761.","DOI":"10.3390\/pharmaceutics15061761"},{"key":"2489_CR323","doi-asserted-by":"crossref","unstructured":"Beck A, Dumontet C, Joubert N. Antibody-drug conjugates in oncology. New strategies in development. Med Sci (Paris). 2019;35:1043-1053.","DOI":"10.1051\/medsci\/2019228"},{"key":"2489_CR324","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1039\/D4MD00637B","volume":"16","author":"Q Yang","year":"2025","unstructured":"Yang Q, Liu Y. Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates. RSC Med Chem. 2025;16:50\u201362.","journal-title":"RSC Med Chem"},{"key":"2489_CR325","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.2174\/1568026618666180118155847","volume":"17","author":"M Frigerio","year":"2017","unstructured":"Frigerio M, Kyle AF. The chemical design and synthesis of linkers used in antibody drug conjugates. Curr Top Med Chem. 2017;17:3393\u2013424.","journal-title":"Curr Top Med Chem"},{"key":"2489_CR326","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/acs.bioconjchem.2c00611","volume":"34","author":"L de Bever","year":"2023","unstructured":"de Bever L, Popal S, van Schaik J, Rubahamya B, van Delft FL, Thurber GM, et al. Generation of DAR1 antibody-drug conjugates for ultrapotent payloads using tailored GlycoConnect technology. Bioconjug Chem. 2023;34:538\u201348.","journal-title":"Bioconjug Chem"},{"key":"2489_CR327","doi-asserted-by":"crossref","unstructured":"Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek JJ. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload. Pharmaceutics. 2023;15:2160.","DOI":"10.3390\/pharmaceutics15082160"},{"key":"2489_CR328","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"2489_CR329","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/psp4.12424","volume":"8","author":"JPF Bai","year":"2019","unstructured":"Bai JPF, Musante CJ, Petanceska S, Zhang L, Zhao L, Zhao P. American Society for Clinical Pharmacology and Therapeutics 2019 annual meeting pre-conferences. CPT Pharmacometrics Syst Pharmacol. 2019;8:333\u20135.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"Suppl 1","key":"2489_CR330","first-page":"S5","volume":"111","author":"American Society for Clinical Pharmacology and Therapeutics","year":"2022","unstructured":"American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther. 2022;111(Suppl 1):S5-s80.","journal-title":"Clin Pharmacol Ther"},{"key":"2489_CR331","doi-asserted-by":"crossref","unstructured":"Zimmerman BS, Esteva FJ. Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer. Cancers (Basel). 2024;16:800.","DOI":"10.3390\/cancers16040800"},{"key":"2489_CR332","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1186\/s12967-024-05453-8","volume":"22","author":"R Wei","year":"2024","unstructured":"Wei R, Zhang W, Yang F, Li Q, Wang Q, Liu N, et al. Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2\/HER2 homodimers and HER2\/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer. J Transl Med. 2024;22:641.","journal-title":"J Transl Med"},{"key":"2489_CR333","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","volume":"34","author":"K Chan","year":"2023","unstructured":"Chan K, Sathyamurthi PS, Queisser MA, Mullin M, Shrives H, Coe DM, et al. Antibody-proteolysis targeting chimera conjugate enables selective degradation of receptor-interacting serine\/threonine-protein kinase 2 in HER2+ cell lines. Bioconjug Chem. 2023;34:2049\u201354.","journal-title":"Bioconjug Chem"},{"key":"2489_CR334","doi-asserted-by":"crossref","unstructured":"Mckertish CM, Kayser V. Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines. 2021;9:872.","DOI":"10.3390\/biomedicines9080872"},{"key":"2489_CR335","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2767-9764.CRC-22-0137","volume":"2","author":"K Krytska","year":"2022","unstructured":"Krytska K, Casey CE, Pogoriler J, Martinez D, Rathi KS, Farrel A, et al. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma. Cancer Res Commun. 2022;2:616\u201323.","journal-title":"Cancer Res Commun"},{"key":"2489_CR336","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101801","volume":"39","author":"FP Fabrizio","year":"2024","unstructured":"Fabrizio FP, Muscarella LA, Rossi A. B7\u2013H3\/CD276 and small-cell lung cancer: what\u2019s new? Transl Oncol. 2024;39:101801.","journal-title":"Transl Oncol"},{"key":"2489_CR337","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","volume":"20","author":"MJ Mair","year":"2023","unstructured":"Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, Brastianos PK, Cortes J, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol. 2023;20:372\u201389.","journal-title":"Nat Rev Clin Oncol"},{"key":"2489_CR338","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11684-024-1072-8","volume":"18","author":"H Zeng","year":"2024","unstructured":"Zeng H, Ning W, Liu X, Luo W, Xia N. Unlocking the potential of bispecific ADCs for targeted cancer therapy. Front Med. 2024;18:597\u2013621.","journal-title":"Front Med"},{"key":"2489_CR339","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","volume":"46","author":"Y Hong","year":"2023","unstructured":"Hong Y, Nam SM, Moon A. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Arch Pharm Res. 2023;46:131\u201348.","journal-title":"Arch Pharm Res"},{"key":"2489_CR340","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104090","volume":"190","author":"I Schlam","year":"2023","unstructured":"Schlam I, Moges R, Morganti S, Tolaney SM, Tarantino P. Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2. Crit Rev Oncol Hematol. 2023;190:104090.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2489_CR341","doi-asserted-by":"crossref","unstructured":"Yajaman DR, Oh Y, Trevino JG, Harrell JC. Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers. Cancers (Basel). 2025;17:1792.","DOI":"10.3390\/cancers17111792"},{"key":"2489_CR342","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U. Antibody-drug conjugates\u2013an emerging class of cancer treatment. Br J Cancer. 2016;114:362\u20137.","journal-title":"Br J Cancer"},{"key":"2489_CR343","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14712598.2023.2285996","volume":"23","author":"JV Leyton","year":"2023","unstructured":"Leyton JV. The endosomal-lysosomal system in ADC design and cancer therapy. Expert Opin Biol Ther. 2023;23:1067\u201376.","journal-title":"Expert Opin Biol Ther"},{"key":"2489_CR344","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. Nat Med. 2025;31:45\u201359.","journal-title":"Nat Med"},{"key":"2489_CR345","doi-asserted-by":"crossref","unstructured":"Sobhani N, D'Angelo A, Pittacolo M, Mondani G, Generali D. Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion. Cancers (Basel). 2024;16:3089.","DOI":"10.3390\/cancers16173089"},{"key":"2489_CR346","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/13543784.2011.582866","volume":"20","author":"P Sapra","year":"2011","unstructured":"Sapra P, Hooper AT, O\u2019Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs. 2011;20:1131\u201349.","journal-title":"Expert Opin Investig Drugs"},{"key":"2489_CR347","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10928-013-9329-x","volume":"40","author":"N Haddish-Berhane","year":"2013","unstructured":"Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, et al. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK\/PD approach. J Pharmacokinet Pharmacodyn. 2013;40:557\u201371.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2489_CR348","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1553853","volume":"16","author":"DE Zhang","year":"2025","unstructured":"Zhang DE, He T, Shi T, Huang K, Peng A. Trends in the research and development of peptide drug conjugates: artificial intelligence aided design. Front Pharmacol. 2025;16:1553853.","journal-title":"Front Pharmacol"},{"key":"2489_CR349","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1021\/acs.jcim.5c00037","volume":"65","author":"L Angiolini","year":"2025","unstructured":"Angiolini L, Manetti F, Spiga O, Tafi A, Visibelli A, Petricci E. Machine learning for predicting the drug-to-antibody ratio (DAR) in the synthesis of antibody-drug conjugates (ADCs). J Chem Inf Model. 2025;65:5847\u201355.","journal-title":"J Chem Inf Model"},{"key":"2489_CR350","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/alz.13533","volume":"20","author":"CE Sexton","year":"2024","unstructured":"Sexton CE, Bitan G, Bowles KR, Brys M, Bu\u00e9e L, Maina MB, et al. Novel avenues of tau research. Alzheimers Dement. 2024;20:2240\u201361.","journal-title":"Alzheimers Dement"},{"key":"2489_CR351","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112266","volume":"134","author":"J Liu","year":"2024","unstructured":"Liu J, He M. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma. Int Immunopharmacol. 2024;134:112266.","journal-title":"Int Immunopharmacol"},{"key":"2489_CR352","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00276","volume":"11","author":"V Janelle","year":"2020","unstructured":"Janelle V, Rulleau C, Del Testa S, Carli C, Delisle JS. T-cell immunotherapies targeting histocompatibility and tumor antigens in hematological malignancies. Front Immunol. 2020;11:276.","journal-title":"Front Immunol"},{"key":"2489_CR353","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00729-7","volume":"6","author":"Y Xu","year":"2021","unstructured":"Xu Y, Su GH, Ma D, Xiao Y, Shao ZM, Jiang YZ. Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. Signal Transduct Target Ther. 2021;6:312.","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"2489_CR354","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1111\/bph.70064","volume":"182","author":"B Srinivasan","year":"2025","unstructured":"Srinivasan B. Time-evolved metrics for safety pharmacological assessments of small molecules and biologics. Br J Pharmacol. 2025;182(13):2831\u201341.","journal-title":"Br J Pharmacol"},{"key":"2489_CR355","doi-asserted-by":"crossref","unstructured":"Zhang Y, Luo M, Wu P, Wu S, Lee TY, Bai C. Application of Computational Biology and Artificial Intelligence in Drug Design. Int J Mol Sci. 2022;23:13568.","DOI":"10.3390\/ijms232113568"},{"key":"2489_CR356","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jconrel.2024.08.049","volume":"375","author":"T Tedeschini","year":"2024","unstructured":"Tedeschini T, Campara B, Grigoletto A, Zanotto I, Cannella L, Gabbia D, et al. Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates. J Control Release. 2024;375:74\u201389.","journal-title":"J Control Release"},{"key":"2489_CR357","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117106","volume":"177","author":"JH Li","year":"2024","unstructured":"Li JH, Liu L, Zhao XH. Precision targeting in oncology: the future of conjugated drugs. Biomed Pharmacother. 2024;177:117106.","journal-title":"Biomed Pharmacother"},{"key":"2489_CR358","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107504","volume":"149","author":"JH Jeon","year":"2024","unstructured":"Jeon JH, Woo Kim S, Kim YJ, Park JW, Eun Moon J, Beom Lee Y, et al. Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload. Bioorg Chem. 2024;149:107504.","journal-title":"Bioorg Chem"},{"key":"2489_CR359","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3389\/fphar.2018.00787","volume":"9","author":"C Wang","year":"2018","unstructured":"Wang C, Xu P, Zhang L, Huang J, Zhu K, Luo C. Current strategies and applications for precision drug design. Front Pharmacol. 2018;9:787.","journal-title":"Front Pharmacol"},{"key":"2489_CR360","doi-asserted-by":"crossref","unstructured":"Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2021;26:5847.","DOI":"10.3390\/molecules26195847"},{"key":"2489_CR361","first-page":"164","volume":"5","author":"M Li","year":"2022","unstructured":"Li M, Mei S, Yang Y, Shen Y, Chen L. Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective. Antib Ther. 2022;5:164\u201376.","journal-title":"Antib Ther"},{"key":"2489_CR362","doi-asserted-by":"crossref","unstructured":"Rao M, McDuffie E, Sachs C. Artificial Intelligence\/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics. Toxics. 2023;11:875.","DOI":"10.3390\/toxics11100875"},{"key":"2489_CR363","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo Y, Shen Z, Zhao W, Lu J, Song Y, Shen L, et al. Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv Sci (Weinh). 2024;11:e2306309.","journal-title":"Adv Sci (Weinh)"},{"key":"2489_CR364","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00764-4","volume":"13","author":"V Dewaker","year":"2025","unstructured":"Dewaker V, Morya VK, Kim YH, Park ST, Kim HS, Koh YH. Revolutionizing oncology: the role of artificial intelligence (AI) as an antibody design, and optimization tools. Biomark Res. 2025;13:52.","journal-title":"Biomark Res"},{"key":"2489_CR365","doi-asserted-by":"crossref","unstructured":"Chen L, Li B, Chen Y, Lin M, Zhang S, Li C, Pang Y, Wang L: ADCNet: a unified framework for predicting the activity of antibody-drug conjugates. Brief Bioinform 2025; 26:bbaf228","DOI":"10.1093\/bib\/bbaf228"},{"key":"2489_CR366","doi-asserted-by":"crossref","unstructured":"Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W, et al. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines. 2024;12:2158.","DOI":"10.3390\/biomedicines12092158"},{"key":"2489_CR367","doi-asserted-by":"crossref","unstructured":"Huemer F, Leisch M, Geisberger R, Melchardt T, Rinnerthaler G, Zaborsky N, et al. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. Int J Mol Sci. 2020;21:2856.","DOI":"10.3390\/ijms21082856"},{"key":"2489_CR368","first-page":"11","volume":"8","author":"\u00c9A Larose","year":"2025","unstructured":"Larose \u00c9A, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resist. 2025;8:11.","journal-title":"Cancer Drug Resist"},{"key":"2489_CR369","doi-asserted-by":"crossref","unstructured":"Mitra A, Kumar A, Amdare NP, Pathak R. Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion. Biology (Basel). 2024;13:307.","DOI":"10.3390\/biology13050307"},{"key":"2489_CR370","doi-asserted-by":"publisher","first-page":"7763","DOI":"10.1038\/s41598-017-08151-2","volume":"7","author":"Y Tang","year":"2017","unstructured":"Tang Y, Tang F, Yang Y, Zhao L, Zhou H, Dong J, et al. Real-time analysis on drug-antibody ratio of antibody-drug conjugates for synthesis, process optimization, and quality control. Sci Rep. 2017;7:7763.","journal-title":"Sci Rep"},{"key":"2489_CR371","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41568-025-00796-w","volume":"25","author":"C Harkos","year":"2025","unstructured":"Harkos C, Hadjigeorgiou AG, Voutouri C, Kumar AS, Stylianopoulos T, Jain RK. Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer. Nat Rev Cancer. 2025;25:324\u201340.","journal-title":"Nat Rev Cancer"},{"key":"2489_CR372","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100054","volume":"36","author":"S Wu","year":"2023","unstructured":"Wu S, Yue M, Zhang J, Li X, Li Z, Zhang H, et al. The role of artificial intelligence in accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in breast cancer. Mod Pathol. 2023;36:100054.","journal-title":"Mod Pathol"},{"key":"2489_CR373","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2025.04.002","volume":"46","author":"Y Tao","year":"2025","unstructured":"Tao Y, Lu Y, Yu B, Wang Y. Molecular glue meets antibody: next-generation antibody-drug conjugates. Trends Pharmacol Sci. 2025;46:520\u201334.","journal-title":"Trends Pharmacol Sci"},{"key":"2489_CR374","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189369","volume":"1880","author":"R Pacholczak-Madej","year":"2025","unstructured":"Pacholczak-Madej R, Meluch M, P\u00fcsk\u00fcll\u00fco\u011flu M. Sequencing of antibody drug conjugates in breast cancer: evidence gap and future directions. Biochim Biophys Acta Rev Cancer. 2025;1880:189369.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2489_CR375","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1021\/acs.analchem.4c04311","volume":"97","author":"K Liu","year":"2025","unstructured":"Liu K, Ai Y, Tan HY, Yuan J, Meissen JK, Zhang Y, et al. Streamlined high-throughput data analysis workflow for antibody-drug conjugate biotransformation characterization. Anal Chem. 2025;97:5919\u201325.","journal-title":"Anal Chem"},{"key":"2489_CR376","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107917","volume":"229","author":"Y Jin","year":"2022","unstructured":"Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022;229:107917.","journal-title":"Pharmacol Ther"},{"key":"2489_CR377","doi-asserted-by":"crossref","unstructured":"Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z, et al. Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics. 2023;15:2233.","DOI":"10.3390\/pharmaceutics15092233"},{"key":"2489_CR378","doi-asserted-by":"crossref","unstructured":"Ertas YN, Abedi Dorcheh K, Akbari A, Jabbari E. Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells: A Review of Recent Advances. Nanomaterials (Basel). 2021;11:1755.","DOI":"10.3390\/nano11071755"},{"key":"2489_CR379","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apsb.2020.09.016","volume":"11","author":"H Duan","year":"2021","unstructured":"Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11:55\u201370.","journal-title":"Acta Pharm Sin B"},{"key":"2489_CR380","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114445","volume":"188","author":"Q Gao","year":"2022","unstructured":"Gao Q, Feng J, Liu W, Wen C, Wu Y, Liao Q, et al. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Adv Drug Deliv Rev. 2022;188:114445.","journal-title":"Adv Drug Deliv Rev"},{"key":"2489_CR381","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10:1367\u2013401.","journal-title":"Genes Dis"},{"key":"2489_CR382","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18433\/J30C7D","volume":"14","author":"M Chidambaram","year":"2011","unstructured":"Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 2011;14:67\u201377.","journal-title":"J Pharm Pharm Sci"},{"key":"2489_CR383","doi-asserted-by":"crossref","unstructured":"Juan A, Cimas FJ, Bravo I, Pandiella A, Oca\u00f1a A, Alonso-Moreno C. Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment. Int J Mol Sci. 2020;21:6018.","DOI":"10.3390\/ijms21176018"},{"key":"2489_CR384","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.2147\/IJN.S386037","volume":"17","author":"NM Hamdy","year":"2022","unstructured":"Hamdy NM, Eskander G, Basalious EB. Insights on the dynamic innovative tumor targeted-nanoparticles-based drug delivery systems activation techniques. Int J Nanomedicine. 2022;17:6131\u201355.","journal-title":"Int J Nanomedicine"},{"key":"2489_CR385","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-023-03913-6","volume":"18","author":"PR Kumbhar","year":"2023","unstructured":"Kumbhar PR, Kumar P, Lasure A, Velayutham R, Mandal D. An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success. Discover Nano. 2023;18:156.","journal-title":"Discover Nano"},{"key":"2489_CR386","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","volume":"200","author":"A Wicki","year":"2015","unstructured":"Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138\u201357.","journal-title":"J Control Release"},{"key":"2489_CR387","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2022.05.032","volume":"34","author":"R Liu","year":"2023","unstructured":"Liu R, Luo C, Pang Z, Zhang J, Ruan S, Wu M, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chin Chem Lett. 2023;34:107518.","journal-title":"Chin Chem Lett"},{"key":"2489_CR388","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1021\/acs.bioconjchem.8b00692","volume":"29","author":"C Gao","year":"2018","unstructured":"Gao C, Bhattarai P, Chen M, Zhang N, Hameed S, Yue X, et al. Amphiphilic drug conjugates as nanomedicines for combined cancer therapy. Bioconjug Chem. 2018;29:3967\u201381.","journal-title":"Bioconjug Chem"},{"key":"2489_CR389","doi-asserted-by":"crossref","unstructured":"Cruz E, Kayser V. Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles. Cancers (Basel). 2019;11:870.","DOI":"10.3390\/cancers11060870"},{"key":"2489_CR390","doi-asserted-by":"crossref","unstructured":"Juan A, Cimas FJ, Bravo I, Pandiella A, Oca\u00f1a A, Alonso-Moreno C. An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. Pharmaceutics. 2020;12:802.","DOI":"10.3390\/pharmaceutics12090802"},{"key":"2489_CR391","doi-asserted-by":"crossref","unstructured":"Yan S, Na J, Liu X, Wu P. Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics. 2024;16:248.","DOI":"10.3390\/pharmaceutics16020248"},{"key":"2489_CR392","doi-asserted-by":"crossref","unstructured":"Spada A, Gerber-Lemaire S. Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting. Nanomaterials (Basel). 2025;15:158.","DOI":"10.3390\/nano15030158"},{"key":"2489_CR393","doi-asserted-by":"crossref","unstructured":"Fu Z, Xiang J. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. Int J Mol Sci. 2020;21:9123.","DOI":"10.3390\/ijms21239123"},{"key":"2489_CR394","doi-asserted-by":"crossref","unstructured":"Kim M, Kim DM, Kim KS, Jung W, Kim DE. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents. Molecules. 2018;23:830.","DOI":"10.3390\/molecules23040830"},{"key":"2489_CR395","doi-asserted-by":"crossref","unstructured":"Rizwanullah M, Ahmad MZ, Ghoneim MM, Alshehri S, Imam SS, Md S, et al. Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges. Pharmaceutics. 2021;13:2039.","DOI":"10.3390\/pharmaceutics13122039"},{"key":"2489_CR396","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cca.2014.05.004","volume":"436","author":"MJ Akhtar","year":"2014","unstructured":"Akhtar MJ, Ahamed M, Alhadlaq HA, Alrokayan SA, Kumar S. Targeted anticancer therapy: overexpressed receptors and nanotechnology. Clin Chim Acta. 2014;436:78\u201392.","journal-title":"Clin Chim Acta"},{"key":"2489_CR397","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1002\/bit.28205","volume":"119","author":"R Kumar","year":"2022","unstructured":"Kumar R, Dkhar DS, Kumari R. Divya, Mahapatra S, Srivastava A, Dubey VK, Chandra P: Ligand conjugated lipid-based nanocarriers for cancer theranostics. Biotechnol Bioeng. 2022;119:3022\u201343.","journal-title":"Biotechnol Bioeng"},{"key":"2489_CR398","doi-asserted-by":"crossref","unstructured":"Brylev VA, Ryabukhina EV, Nazarova EV, Samoylenkova NS, Gulyak EL, Sapozhnikova KA, et al. Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker. Pharmaceutics. 2024;16:1434.","DOI":"10.3390\/pharmaceutics16111434"},{"key":"2489_CR399","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01181","volume":"8","author":"R Razpotnik","year":"2017","unstructured":"Razpotnik R, Novak N, \u010curin \u0160erbec V, Rajcevic U. Targeting malignant brain tumors with antibodies. Front Immunol. 2017;8:1181.","journal-title":"Front Immunol"},{"key":"2489_CR400","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1007\/s13346-022-01173-y","volume":"12","author":"TG Agnihotri","year":"2022","unstructured":"Agnihotri TG, Jadhav GS, Sahu B, Jain A. Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders. Drug Deliv Transl Res. 2022;12:3104\u201320.","journal-title":"Drug Deliv Transl Res"},{"key":"2489_CR401","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858\u201383.","journal-title":"Clin Microbiol Rev"},{"key":"2489_CR402","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","volume":"25","author":"LL Muldoon","year":"2007","unstructured":"Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295\u2013305.","journal-title":"J Clin Oncol"},{"key":"2489_CR403","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","volume":"161","author":"S Wohlfart","year":"2012","unstructured":"Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2012;161:264\u201373.","journal-title":"J Control Release"},{"key":"2489_CR404","doi-asserted-by":"crossref","unstructured":"Tashima T. Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates. Biomedicines. 2022;10:1597.","DOI":"10.3390\/biomedicines10071597"},{"key":"2489_CR405","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202203678","volume":"18","author":"L Wang","year":"2022","unstructured":"Wang L, Shi Y, Jiang J, Li C, Zhang H, Zhang X, et al. Micro-nanocarriers based drug delivery technology for blood-brain barrier crossing and brain tumor targeting therapy. Small. 2022;18:e2203678.","journal-title":"Small"},{"key":"2489_CR406","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.2147\/IJN.S117210","volume":"11","author":"DB Vieira","year":"2016","unstructured":"Vieira DB, Gamarra LF. Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. Int J Nanomedicine. 2016;11:5381\u2013414.","journal-title":"Int J Nanomedicine"},{"key":"2489_CR407","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jconrel.2022.06.011","volume":"348","author":"S Bashyal","year":"2022","unstructured":"Bashyal S, Thapa C, Lee S. Recent progresses in exosome-based systems for targeted drug delivery to the brain. J Control Release. 2022;348:723\u201344.","journal-title":"J Control Release"},{"key":"2489_CR408","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03731-z","volume":"25","author":"AE Basyoni","year":"2025","unstructured":"Basyoni AE, Atta A, Salem MM, Mohamed TM. Harnessing exosomes for targeted drug delivery systems to combat brain cancer. Cancer Cell Int. 2025;25:150.","journal-title":"Cancer Cell Int"},{"key":"2489_CR409","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1007\/s12035-023-03365-0","volume":"60","author":"SH Khatami","year":"2023","unstructured":"Khatami SH, Karami N, Taheri-Anganeh M, Taghvimi S, Tondro G, Khorsand M, et al. Exosomes: promising delivery tools for overcoming blood-brain barrier and glioblastoma therapy. Mol Neurobiol. 2023;60:4659\u201378.","journal-title":"Mol Neurobiol"},{"key":"2489_CR410","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2023.102930","volume":"317","author":"S Kans\u0131z","year":"2023","unstructured":"Kans\u0131z S, El\u00e7in YM. Advanced liposome and polymersome-based drug delivery systems: considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches. Adv Colloid Interface Sci. 2023;317:102930.","journal-title":"Adv Colloid Interface Sci"},{"key":"2489_CR411","doi-asserted-by":"publisher","first-page":"22673","DOI":"10.1021\/acsami.0c05724","volume":"12","author":"H Chen","year":"2020","unstructured":"Chen H, Luo Q, Wang J, He H, Luo W, Zhang L, et al. Response of pH-sensitive doxorubicin nanoparticles on complex tumor microenvironments by tailoring multiple physicochemical properties. ACS Appl Mater Interfaces. 2020;12:22673\u201386.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2489_CR412","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1021\/acsnano.6b02326","volume":"10","author":"HJ Li","year":"2016","unstructured":"Li HJ, Du JZ, Liu J, Du XJ, Shen S, Zhu YH, et al. Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano. 2016;10:6753\u201361.","journal-title":"ACS Nano"},{"key":"2489_CR413","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biomaterials.2016.01.061","volume":"85","author":"M Kanamala","year":"2016","unstructured":"Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152\u201367.","journal-title":"Biomaterials"},{"key":"2489_CR414","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.biotechadv.2013.11.009","volume":"32","author":"J Liu","year":"2014","unstructured":"Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, et al. Ph-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014;32:693\u2013710.","journal-title":"Biotechnol Adv"},{"key":"2489_CR415","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102821","volume":"56","author":"A Xie","year":"2020","unstructured":"Xie A, Hanif S, Ouyang J, Tang Z, Kong N, Kim NY, et al. Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine. 2020;56:102821.","journal-title":"EBioMedicine"},{"key":"2489_CR416","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1021\/acs.chemrev.2c00915","volume":"123","author":"L Qian","year":"2023","unstructured":"Qian L, Lin X, Gao X, Khan RU, Liao JY, Du S, et al. The Dawn of a New Era: Targeting the \u201cUndruggables\u201d with Antibody-Based Therapeutics. Chem Rev. 2023;123:7782\u2013853.","journal-title":"Chem Rev"},{"key":"2489_CR417","doi-asserted-by":"publisher","first-page":"23223","DOI":"10.1021\/acsnano.3c06019","volume":"17","author":"D Wei","year":"2023","unstructured":"Wei D, Sun Y, Zhu H, Fu Q. Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 2023;17:23223\u201361.","journal-title":"ACS Nano"},{"key":"2489_CR418","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","volume":"12","author":"X Shan","year":"2022","unstructured":"Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12:3028\u201348.","journal-title":"Acta Pharm Sin B"},{"key":"2489_CR419","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","volume":"52","author":"H He","year":"2019","unstructured":"He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures. Acc Chem Res. 2019;52:2445\u201361.","journal-title":"Acc Chem Res"},{"key":"2489_CR420","doi-asserted-by":"crossref","unstructured":"Working PK, S. NM, K. HS, E. M, J. V, and Lasic DD: Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth\u00ae Liposomes (Doxil\u00ae). Journal of Liposome Research 1994, 4:667\u2013687.","DOI":"10.3109\/08982109409037065"},{"key":"2489_CR421","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae\u2013the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334.","journal-title":"J Control Release"},{"key":"2489_CR422","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/1061186X.2023.2295803","volume":"32","author":"A Al-Taie","year":"2024","unstructured":"Al-Taie A, \u00d6zcan B\u00fclb\u00fcl E. A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches. J Drug Target. 2024;32:45\u201356.","journal-title":"J Drug Target"},{"key":"2489_CR423","doi-asserted-by":"crossref","unstructured":"Li Q, Li W, Xu K, Xing Y, Shi H, Jing Z, et al. PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates. Int J Mol Sci. 2021;22:1540.","DOI":"10.3390\/ijms22041540"},{"key":"2489_CR424","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2020.08.004","volume":"327","author":"F Brandl","year":"2020","unstructured":"Brandl F, Busslinger S, Zangemeister-Wittke U, Pl\u00fcckthun A. Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. J Control Release. 2020;327:186\u201397.","journal-title":"J Control Release"},{"key":"2489_CR425","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202409635","volume":"21","author":"A Adhikari","year":"2025","unstructured":"Adhikari A, Chen IA. Antibody-nanoparticle conjugates in therapy: combining the best of two worlds. Small. 2025;21:e2409635.","journal-title":"Small"},{"key":"2489_CR426","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","volume":"33","author":"AD Santin","year":"2023","unstructured":"Santin AD, Vergote I, Gonz\u00e1lez-Mart\u00edn A, Moore K, Oaknin A, Romero I, et al. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. Int J Gynecol Cancer. 2023;33:562\u201370.","journal-title":"Int J Gynecol Cancer"},{"key":"2489_CR427","doi-asserted-by":"publisher","first-page":"34103","DOI":"10.18632\/oncotarget.26135","volume":"9","author":"M Quanz","year":"2018","unstructured":"Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, et al. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. Oncotarget. 2018;9:34103\u201321.","journal-title":"Oncotarget"},{"key":"2489_CR428","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113682","volume":"382","author":"J Li","year":"2025","unstructured":"Li J, Al Faruque H, Li S, Sima M, Sborov D, Hu-Lieskovan S, et al. PD-L1 targeted antibody-polymer-epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. J Control Release. 2025;382:113682.","journal-title":"J Control Release"},{"key":"2489_CR429","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-021-06423-0","volume":"191","author":"ETR Torres","year":"2022","unstructured":"Torres ETR, Emens LA. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. Breast Cancer Res Treat. 2022;191:291\u2013302.","journal-title":"Breast Cancer Res Treat"},{"key":"2489_CR430","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.339","volume":"4","author":"Y Hao","year":"2023","unstructured":"Hao Y, Ji Z, Zhou H, Wu D, Gu Z, Wang D, et al. Lipid-based nanoparticles as drug delivery systems for cancer immunotherapy. MedComm. 2023;4:e339.","journal-title":"MedComm"},{"key":"2489_CR431","doi-asserted-by":"crossref","unstructured":"Fobian SF, Cheng Z, Ten Hagen TLM. Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks. Pharmaceutics. 2021;14:26.","DOI":"10.3390\/pharmaceutics14010026"},{"key":"2489_CR432","doi-asserted-by":"publisher","first-page":"8519","DOI":"10.1021\/acs.jmedchem.4c00568","volume":"67","author":"KA Iyer","year":"2024","unstructured":"Iyer KA, Ivanov J, Tenchov R, Ralhan K, Rodriguez Y, Sasso JM, et al. Emerging targets and therapeutics in immuno-oncology: insights from landscape analysis. J Med Chem. 2024;67:8519\u201344.","journal-title":"J Med Chem"},{"key":"2489_CR433","first-page":"6","volume":"4","author":"V Ejigah","year":"2022","unstructured":"Ejigah V, Mandala B, Akala EO. Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer. J Cancer Metastasis Res. 2022;4:6\u201322.","journal-title":"J Cancer Metastasis Res"},{"key":"2489_CR434","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0012","volume":"4","author":"JH Lee","year":"2023","unstructured":"Lee JH, Chapman DV, Saltzman WM. Nanoparticle targeting with antibodies in the central nervous system. BME Front. 2023;4:0012.","journal-title":"BME Front"},{"key":"2489_CR435","doi-asserted-by":"crossref","unstructured":"Battogtokh G, Obidiro O, Akala EO. Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC). Cancers (Basel). 2024;16:2012.","DOI":"10.3390\/cancers16112012"},{"key":"2489_CR436","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41:22\u201331.","journal-title":"J Clin Oncol"},{"key":"2489_CR437","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","volume":"26","author":"S Gupta","year":"2025","unstructured":"Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, et al. Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2025;26:795\u2013805.","journal-title":"Lancet Oncol"},{"key":"2489_CR438","doi-asserted-by":"publisher","first-page":"TPS3154","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3154","volume":"40","author":"A Patnaik","year":"2022","unstructured":"Patnaik A, Call JA, Spreafico A, Nabell L, Yan M, Forero-Torres A, et al. Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody\u2013drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress). J Clin Oncol. 2022;40:TPS3154\u2013TPS3154.","journal-title":"J Clin Oncol"},{"key":"2489_CR439","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121184","volume":"279","author":"DM Francis","year":"2021","unstructured":"Francis DM, Manspeaker MP, Archer PA, Sestito LF, Heiler AJ, Schudel A, et al. Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting. Biomaterials. 2021;279:121184.","journal-title":"Biomaterials"},{"key":"2489_CR440","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/PPO.0000000000000631","volume":"28","author":"R Prakash","year":"2022","unstructured":"Prakash R, Subbiah V, Iyer SP. Evolving landscape of antibody drug conjugates in lymphoma. Cancer J. 2022;28:479\u201387.","journal-title":"Cancer J"},{"key":"2489_CR441","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.phrs.2016.03.002","volume":"107","author":"M Truffi","year":"2016","unstructured":"Truffi M, Fiandra L, Sorrentino L, Monieri M, Corsi F, Mazzucchelli S. Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol Res. 2016;107:57\u201365.","journal-title":"Pharmacol Res"},{"key":"2489_CR442","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/nnm.12.95","volume":"8","author":"R Kaur","year":"2013","unstructured":"Kaur R, Badea I. Nanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systems. Int J Nanomedicine. 2013;8:203\u201320.","journal-title":"Int J Nanomedicine"},{"key":"2489_CR443","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","volume":"32","author":"GT Noble","year":"2014","unstructured":"Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32:32\u201345.","journal-title":"Trends Biotechnol"},{"key":"2489_CR444","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2147\/IJN.S236927","volume":"15","author":"U Ruman","year":"2020","unstructured":"Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ. Nanocarrier-based therapeutics and theranostics drug delivery systems for next generation of liver cancer nanodrug modalities. Int J Nanomedicine. 2020;15:1437\u201356.","journal-title":"Int J Nanomedicine"},{"key":"2489_CR445","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jconrel.2011.06.032","volume":"155","author":"S Ibsen","year":"2011","unstructured":"Ibsen S, Benchimol M, Simberg D, Schutt C, Steiner J, Esener S. A novel nested liposome drug delivery vehicle capable of ultrasound triggered release of its payload. J Control Release. 2011;155:358\u201366.","journal-title":"J Control Release"},{"key":"2489_CR446","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nmat2564","volume":"8","author":"MS Yavuz","year":"2009","unstructured":"Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, Rycenga M, et al. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater. 2009;8:935\u20139.","journal-title":"Nat Mater"},{"key":"2489_CR447","doi-asserted-by":"publisher","unstructured":"Dey T, Ghosh A, Sanyal A, Charles CJ, Pokharel S, Nair L, et al. Surface engineered nanodiamonds: mechanistic intervention in biomedical applications for diagnosis and treatment of cancer. Biomed Mater. 2024. https:\/\/doi.org\/10.1088\/1748-605X\/ad3abb","DOI":"10.1088\/1748-605X\/ad3abb"},{"key":"2489_CR448","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202407793","volume":"36","author":"XJ Gao","year":"2024","unstructured":"Gao XJ, Ciura K, Ma Y, Mikolajczyk A, Jagiello K, Wan Y, et al. Toward the integration of machine learning and molecular modeling for designing drug delivery nanocarriers. Adv Mater. 2024;36:e2407793.","journal-title":"Adv Mater"},{"key":"2489_CR449","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114194","volume":"184","author":"N Serov","year":"2022","unstructured":"Serov N, Vinogradov V. Artificial intelligence to bring nanomedicine to life. Adv Drug Deliv Rev. 2022;184:114194.","journal-title":"Adv Drug Deliv Rev"},{"key":"2489_CR450","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2147\/IJN.S344208","volume":"17","author":"Z Lin","year":"2022","unstructured":"Lin Z, Chou WC, Cheng YH, He C, Monteiro-Riviere NA, Riviere JE. Predicting nanoparticle delivery to tumors using machine learning and artificial intelligence approaches. Int J Nanomedicine. 2022;17:1365\u201379.","journal-title":"Int J Nanomedicine"},{"key":"2489_CR451","doi-asserted-by":"publisher","first-page":"22579","DOI":"10.18632\/oncotarget.8022","volume":"7","author":"CC Roskopf","year":"2016","unstructured":"Roskopf CC, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, et al. Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget. 2016;7:22579\u201389.","journal-title":"Oncotarget"},{"key":"2489_CR452","doi-asserted-by":"crossref","unstructured":"Shramova E, Proshkina G, Shipunova V, Ryabova A, Kamyshinsky R, Konevega A, et al. Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape. Cancers (Basel). 2020;12:3014.","DOI":"10.3390\/cancers12103014"},{"key":"2489_CR453","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41401-024-01458-7","volume":"46","author":"M Wang","year":"2025","unstructured":"Wang M, Ma Q, Suthe SR, Hudson RE, Pan JY, Mikelis C, et al. Humanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity. Acta Pharmacol Sin. 2025;46:1375\u201389.","journal-title":"Acta Pharmacol Sin"},{"key":"2489_CR454","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2022.06.044","volume":"349","author":"YD Taghipour","year":"2022","unstructured":"Taghipour YD, Zarebkohan A, Salehi R, Rahimi F, Torchilin VP, Hamblin MR, et al. An update on dual targeting strategy for cancer treatment. J Control Release. 2022;349:67\u201396.","journal-title":"J Control Release"},{"key":"2489_CR455","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1158\/1535-7163.MCT-21-0335","volume":"20","author":"S Tsujii","year":"2021","unstructured":"Tsujii S, Serada S, Fujimoto M, Uemura S, Namikawa T, Nomura T, et al. Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer. Mol Cancer Ther. 2021;20:2495\u2013505.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR456","doi-asserted-by":"crossref","unstructured":"Yu X, Long Y, Chen B, Tong Y, Shan M, Jia X, et al. PD-L1\/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. J Immunother Cancer. 2022;10:e004590.","DOI":"10.1136\/jitc-2022-004590"},{"key":"2489_CR457","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-4776","volume":"85","author":"T Yi","year":"2025","unstructured":"Yi T, Yang L, Hao K, Cao W, Qi Y, Gai J, et al. Abstract 4776: preclinical study of bispecific antibody drug conjugates (bsADCs) targeting DLL3 and SEZ6 demonstrated potent anti-tumor activity in small cell lung cancer (SCLC) xenograft models. Cancer Res. 2025;85:4776\u20134776.","journal-title":"Cancer Res"},{"key":"2489_CR458","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1158\/1538-7445.AM2025-340","volume":"85","author":"X Chai","year":"2025","unstructured":"Chai X, Li F, Xie H, Lu Y, Li N, Yu H, et al. Abstract 340: gensci139, a highly differentiated EGFR\u00d7HER2 bispecific ADC, for the treatment of multiple solid tumors. Cancer Res. 2025;85:340\u2013340.","journal-title":"Cancer Res"},{"key":"2489_CR459","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)33058-1","volume":"23","author":"D Richards","year":"2012","unstructured":"Richards D, Braiteh F, Anthony S, Edenfield W, Hellerstedt B, Raju R, et al. 496p - a phase 1 study of MM-111; a bispecific HER2\/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2 positive solid tumors. Ann Oncol. 2012;23:ix170.","journal-title":"Ann Oncol"},{"key":"2489_CR460","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473148","volume":"45","author":"L Guidi","year":"2025","unstructured":"Guidi L, Etessami J, Valenza C, Valdivia A, Meric-Bernstam F, Felip E, et al. Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances. Am Soc Clin Oncol Educ Book. 2025;45:e473148.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2489_CR461","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, et al. Bispecific antibodies: advancing precision oncology. Trends Cancer. 2024;10:893\u2013919.","journal-title":"Trends Cancer"},{"key":"2489_CR462","doi-asserted-by":"crossref","unstructured":"Elshiaty M, Schindler H, Christopoulos P. Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. Int J Mol Sci. 2021;22:5632.","DOI":"10.3390\/ijms22115632"},{"key":"2489_CR463","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1158\/1538-7445.AM2025-2955","volume":"85","author":"L Qi","year":"2025","unstructured":"Qi L, Takeda S, Zhang Y, Huang M, Zhou D, Mao Y, et al. Abstract 2955: preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7\u2013H3 for the treatment of solid cancers. Cancer Res. 2025;85:2955\u20132955.","journal-title":"Cancer Res"},{"key":"2489_CR464","doi-asserted-by":"crossref","unstructured":"Ettorre VM, AlAshqar A, Sethi N, Santin AD. Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers. Cancers (Basel). 2025;17:1822.","DOI":"10.3390\/cancers17111822"},{"key":"2489_CR465","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591191","volume":"16","author":"F Zhang","year":"2025","unstructured":"Zhang F, Li S. Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions. Front Immunol. 2025;16:1591191.","journal-title":"Front Immunol"},{"key":"2489_CR466","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/jamaoncol.2024.0008","volume":"10","author":"D Trapani","year":"2024","unstructured":"Trapani D, Katrini J, Curigliano G. Unveiling the untapped potential of antibody drug conjugates in precision oncology. JAMA Oncol. 2024;10:563\u20134.","journal-title":"JAMA Oncol"},{"key":"2489_CR467","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/pharmrev.123.001084","volume":"76","author":"Z Huang","year":"2024","unstructured":"Huang Z, Braunstein Z, Chen J, Wei Y, Rao X, Dong L, et al. Precision medicine in rheumatic diseases: unlocking the potential of antibody-drug conjugates. Pharmacol Rev. 2024;76:579\u201398.","journal-title":"Pharmacol Rev"},{"key":"2489_CR468","doi-asserted-by":"crossref","unstructured":"Vitiello A, Ferrara F, Lasala R, Zovi A. Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies. Cancers (Basel). 2022;14:5167.","DOI":"10.3390\/cancers14205167"},{"key":"2489_CR469","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2413686122","volume":"122","author":"X Bai","year":"2025","unstructured":"Bai X, Xu L, Wang Z, Zhuang X, Ning J, Sun Y, et al. Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody-drug conjugates. Proc Natl Acad Sci U S A. 2025;122:e2413686122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2489_CR470","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_431766","volume":"44","author":"L Ascione","year":"2024","unstructured":"Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, et al. Unlocking the potential: Biomarkers of response to antibody-drug conjugates. Am Soc Clin Oncol Educ Book. 2024;44:e431766.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2489_CR471","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308604","volume":"19","author":"U Kathad","year":"2024","unstructured":"Kathad U, Biyani N. Peru YCDPRL, Zhou J, Kochat H, Bhatia K: Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis. PLoS ONE. 2024;19:e0308604.","journal-title":"PLoS ONE"},{"key":"2489_CR472","doi-asserted-by":"crossref","unstructured":"Tagde P, Najda A, Nagpal K, Kulkarni GT, Shah M, Ullah O, et al. Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management. Int J Mol Sci. 2022;23:2856.","DOI":"10.3390\/ijms23052856"},{"key":"2489_CR473","doi-asserted-by":"crossref","unstructured":"Wang Y, Jin RU, Xu J, Lin DC, Sun Z, Xu Y, et al. Harnessing technologies to unravel gastric cancer heterogeneity. Trends Cancer. 2025;11:753-769.","DOI":"10.1016\/j.trecan.2025.04.011"},{"key":"2489_CR474","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.62347\/MWNZ5609","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang C, Li N, Zhang P, Jiang Z, Cheng Y, Li H, et al. Advancing precision and personalized breast cancer treatment through multi-omics technologies. Am J Cancer Res. 2024;14:5614\u201327.","journal-title":"Am J Cancer Res"},{"key":"2489_CR475","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-6851","volume":"85","author":"S Cairo","year":"2025","unstructured":"Cairo S, Gilardi M, Zipeto M, Ritchie M. Abstract 6851: an integrated preclinical platform for antibody-drug conjugate development. Cancer Res. 2025;85:6851\u20136851.","journal-title":"Cancer Res"},{"key":"2489_CR476","doi-asserted-by":"crossref","unstructured":"Stojchevski R, Sutanto EA, Sutanto R, Hadzi-Petrushev N, Mladenov M, Singh SR, et al. Translational Advances in Oncogene and Tumor-Suppressor Gene Research. Cancers (Basel). 2025;17:1008.","DOI":"10.3390\/cancers17061008"},{"key":"2489_CR477","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1152470","volume":"14","author":"G Di Sario","year":"2023","unstructured":"Di Sario G, Rossella V, Famulari ES, Maurizio A, Lazarevic D, Giannese F, et al. Enhancing clinical potential of liquid biopsy through a multi-omic approach: a systematic review. Front Genet. 2023;14:1152470.","journal-title":"Front Genet"},{"key":"2489_CR478","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/2159-8290.CD-24-0218","volume":"14","author":"YW Zhang","year":"2024","unstructured":"Zhang YW, Gvozdenovic A, Aceto N. A molecular voyage: multiomics insights into circulating tumor cells. Cancer Discov. 2024;14:920\u201333.","journal-title":"Cancer Discov"},{"key":"2489_CR479","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06434-1","volume":"23","author":"I Cela","year":"2025","unstructured":"Cela I, Capone E, Pece A, Lovato G, Simeone P, Colasante M, et al. Lgals3bp antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth. J Transl Med. 2025;23:431.","journal-title":"J Transl Med"},{"key":"2489_CR480","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1016\/j.chempr.2023.06.011","volume":"9","author":"C Lu","year":"2023","unstructured":"Lu C, Li Z, Wu N, Lu D, Zhang X-B, Song G. Tumor microenvironment-tailored nanoplatform for companion diagnostic applications of precise cancer therapy. Chem. 2023;9:3185\u2013211.","journal-title":"Chem"},{"key":"2489_CR481","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107086","volume":"201","author":"M Puccetti","year":"2024","unstructured":"Puccetti M, Pariano M, Schoubben A, Giovagnoli S, Ricci M. Biologics, theranostics, and personalized medicine in drug delivery systems. Pharmacol Res. 2024;201:107086.","journal-title":"Pharmacol Res"},{"key":"2489_CR482","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5644\/ama2006-124.325","volume":"50","author":"S Vranic","year":"2021","unstructured":"Vranic S, Gatalica Z. The role of pathology in the era of personalized (precision) medicine: a brief review. Acta Med Acad. 2021;50:47\u201357.","journal-title":"Acta Med Acad"},{"key":"2489_CR483","doi-asserted-by":"publisher","DOI":"10.1177\/11772719211047763","volume":"16","author":"V Valla","year":"2021","unstructured":"Valla V, Alzabin S, Koukoura A, Lewis A, Nielsen AA, Vassiliadis E. Companion diagnostics: state of the art and new regulations. Biomark Insights. 2021;16:11772719211047763.","journal-title":"Biomark Insights"},{"key":"2489_CR484","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202200062","volume":"34","author":"J Wu","year":"2022","unstructured":"Wu J, Zhang Y, Jiang K, Wang X, Blum NT, Zhang J, et al. Enzyme-engineered conjugated polymer nanoplatform for activatable companion diagnostics and multistage augmented synergistic therapy. Adv Mater. 2022;34:e2200062.","journal-title":"Adv Mater"},{"key":"2489_CR485","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101608","volume":"8","author":"G Antonarelli","year":"2023","unstructured":"Antonarelli G, Corti C, Tarantino P, Salimbeni BT, Zagami P, Marra A, et al. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure. ESMO Open. 2023;8:101608.","journal-title":"ESMO Open"},{"key":"2489_CR486","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","volume":"66","author":"E Rassy","year":"2022","unstructured":"Rassy E, Rached L, Pistilli B. Antibody drug conjugates targeting HER2: clinical development in metastatic breast cancer. Breast. 2022;66:217\u201326.","journal-title":"Breast"},{"key":"2489_CR487","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15:24.","journal-title":"J Hematol Oncol"},{"key":"2489_CR488","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105366","volume":"116","author":"D Xiao","year":"2021","unstructured":"Xiao D, Luo L, Li J, Wang Z, Liu L, Xie F, et al. Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem. 2021;116:105366.","journal-title":"Bioorg Chem"},{"key":"2489_CR489","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s10120-025-01584-z","volume":"28","author":"P Zhang","year":"2025","unstructured":"Zhang P, Tao C, Xie H, Yang L, Lu Y, Xi Y, et al. Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody-drug conjugate development. Gastric Cancer. 2025;28:422\u201341.","journal-title":"Gastric Cancer"},{"key":"2489_CR490","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217453","volume":"611","author":"M Usama","year":"2025","unstructured":"Usama M, Hsu YC, Safaei M, Chen CY, Han KH, Ho YS, et al. Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells. Cancer Lett. 2025;611:217453.","journal-title":"Cancer Lett"},{"key":"2489_CR491","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1158\/1538-7445.AM2025-4723","volume":"85","author":"X Hao","year":"2025","unstructured":"Hao X, Liu J, li h, li j, wang j, Hu H-H, et al. Abstract 4723: development and preclinical activity of BSI-721, a novel antibody-drug conjugate (ADC) targeting cadherin 17 (CDH17) in gastrointestinal cancers. Cancer Res. 2025;85:4723\u20134723.","journal-title":"Cancer Res"},{"key":"2489_CR492","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ygyno.2024.01.016","volume":"184","author":"AK Wehn","year":"2024","unstructured":"Wehn AK, Qiu P, Lunceford J, Yarunin A, Cristescu R, Liu L, et al. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer. Gynecol Oncol. 2024;184:67\u201373.","journal-title":"Gynecol Oncol"},{"key":"2489_CR493","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12282-024-01556-8","volume":"32","author":"H Ohmura","year":"2025","unstructured":"Ohmura H, Hanamura F, Okumura Y, Ando Y, Masuda T, Mimori K, et al. Liquid biopsy for breast cancer and other solid tumors: a review of recent advances. Breast Cancer. 2025;32:33\u201342.","journal-title":"Breast Cancer"},{"key":"2489_CR494","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101207","volume":"79","author":"Y Ju","year":"2025","unstructured":"Ju Y, Watson J, Wang JJ, Yen YT, Gevorkian L, Chen Z, et al. B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer. Drug Resist Updat. 2025;79:101207.","journal-title":"Drug Resist Updat"},{"key":"2489_CR495","doi-asserted-by":"publisher","first-page":"132","DOI":"10.22270\/jddt.v15i5.7112","volume":"15","author":"TA Ikwelle","year":"2025","unstructured":"Ikwelle TA, Ihim AC, Ozuruoke DFN, Obi PC, Obi CU, Onuora IJ, et al. Multi-omics integration in personalized medicine: advancing laboratory diagnostics and precision therapeutics in the era of individualized healthcare. J Drug Deliv Ther. 2025;15:132\u201342.","journal-title":"J Drug Deliv Ther"},{"key":"2489_CR496","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2 E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395.","journal-title":"Cancer Treat Rev"},{"key":"2489_CR497","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301\u201319.","journal-title":"Nat Rev Drug Discov"},{"key":"2489_CR498","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106849","volume":"107","author":"J Chandra","year":"2025","unstructured":"Chandra J, Molugulu N, Gupta G, Siddiqua A, Wahab S, Kesharwani P. Biomimetic nanoparticles: a revolutionary approach to breast cancer therapy using cell membrane coatings. J Drug Deliv Sci Technol. 2025;107:106849.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2489_CR499","doi-asserted-by":"publisher","DOI":"10.1002\/smsc.202400113","volume":"4","author":"M Puzzo","year":"2024","unstructured":"Puzzo M, De Santo M, Morelli C, Leggio A, Pasqua L. The advent of molecular targeted therapies against cancer. Toward multi-targeting drugs through materials engineering: a possible future scenario. Small Sci. 2024;4:2400113.","journal-title":"Small Sci"},{"key":"2489_CR500","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02782-6","volume":"42","author":"MN Kiani","year":"2025","unstructured":"Kiani MN, Khaliq H, Abubakar M, Rafique M, Jalilov F, Ashraf GA, et al. Advancing the potential of nanoparticles for cancer detection and precision therapeutics. Med Oncol. 2025;42:239.","journal-title":"Med Oncol"},{"key":"2489_CR501","doi-asserted-by":"crossref","unstructured":"Song CH, Jeong M, In H, Kim JH, Lin CW, Han KH. Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies (Basel). 2023;12:72.","DOI":"10.3390\/antib12040072"},{"key":"2489_CR502","doi-asserted-by":"publisher","first-page":"1259784","DOI":"10.3389\/fonc.2023.1259784","volume":"13","author":"K Li","year":"2023","unstructured":"Li K, Xie G, Deng X, Zhang Y, Jia Z, Huang Z. Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives. Front Oncol. 2023;13:1259784.","journal-title":"Front Oncol"},{"key":"2489_CR503","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56:836\u201349.","journal-title":"Exp Mol Med"},{"key":"2489_CR504","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.7150\/thno.72594","volume":"12","author":"Z Chen","year":"2022","unstructured":"Chen Z, Kankala RK, Yang Z, Li W, Xie S, Li H, et al. Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects. Theranostics. 2022;12:3719\u201346.","journal-title":"Theranostics"},{"key":"2489_CR505","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1039\/D4NA00501E","volume":"6","author":"SS Palakurthi","year":"2024","unstructured":"Palakurthi SS, Shah B, Kapre S, Charbe N, Immanuel S, Pasham S, et al. A comprehensive review of challenges and advances in exosome-based drug delivery systems. Nanoscale Adv. 2024;6:5803\u201326.","journal-title":"Nanoscale Adv"},{"key":"2489_CR506","doi-asserted-by":"crossref","unstructured":"Marques AC, Costa PC, Velho S, Amaral MH. Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy. Pharmaceutics. 2023;15:216.","DOI":"10.3390\/pharmaceutics15010216"},{"key":"2489_CR507","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2012.04.008","volume":"262","author":"JG Reynolds","year":"2012","unstructured":"Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol. 2012;262:1\u201310.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2489_CR508","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","volume":"119","author":"P Munster","year":"2018","unstructured":"Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018;119:1086\u201393.","journal-title":"Br J Cancer"},{"key":"2489_CR509","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13550-015-0096-0","volume":"5","author":"DF Gaddy","year":"2015","unstructured":"Gaddy DF, Lee H, Zheng J, Jaffray DA, Wickham TJ, Hendriks BS. Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2\/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015;5:24.","journal-title":"EJNMMI Res"},{"key":"2489_CR510","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41551-024-01214-6","volume":"8","author":"OPB Wiklander","year":"2024","unstructured":"Wiklander OPB, Mamand DR, Mohammad DK, Zheng W, Jawad Wiklander R, Sych T, et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat Biomed Eng. 2024;8:1453\u201368.","journal-title":"Nat Biomed Eng"},{"key":"2489_CR511","doi-asserted-by":"publisher","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","volume":"16","author":"R Tenchov","year":"2022","unstructured":"Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA. Exosomes\u2500nature\u2019s lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano. 2022;16:17802\u201346.","journal-title":"ACS Nano"},{"key":"2489_CR512","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110442","volume":"129","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Hasan A, Nejadi Babadaei MM, Behzadi E, Nouri M, Sharifi M, et al. Exosomes: multiple-targeted multifunctional biological nanoparticles in the diagnosis, drug delivery, and imaging of cancer cells. Biomed Pharmacother. 2020;129:110442.","journal-title":"Biomed Pharmacother"},{"key":"2489_CR513","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"X Li","year":"2024","unstructured":"Li X, Peng X, Zoulikha M, Boafo GF, Magar KT, Ju Y, et al. Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct Target Ther. 2024;9:1.","journal-title":"Signal Transduct Target Ther"},{"key":"2489_CR514","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01382-y","volume":"8","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8:124.","journal-title":"Signal Transduct Target Ther"},{"key":"2489_CR515","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70005","volume":"13","author":"RT Miceli","year":"2024","unstructured":"Miceli RT, Chen TY, Nose Y, Tichkule S, Brown B, Fullard JF, et al. Extracellular vesicles, RNA sequencing, and bioinformatic analyses: challenges, solutions, and recommendations. J Extracell Vesicles. 2024;13:e70005.","journal-title":"J Extracell Vesicles"},{"key":"2489_CR516","doi-asserted-by":"crossref","unstructured":"Verma N, Arora S. Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions. Pharmaceutics. 2025;17:990.","DOI":"10.3390\/pharmaceutics17080990"},{"key":"2489_CR517","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2385-z","volume":"16","author":"K Miller","year":"2016","unstructured":"Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, et al. HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician\u2019s choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer. BMC Cancer. 2016;16:352.","journal-title":"BMC Cancer"},{"key":"2489_CR518","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1021\/ar700093f","volume":"41","author":"I Ojima","year":"2008","unstructured":"Ojima I. Guided molecular missiles for tumor-targeting chemotherapy\u2013case studies using the second-generation taxoids as warheads. Acc Chem Res. 2008;41:108\u201319.","journal-title":"Acc Chem Res"},{"key":"2489_CR519","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccell.2017.03.009","volume":"31","author":"KA Khan","year":"2017","unstructured":"Khan KA, Kerbel RS. A CD276 antibody guided missile with one warhead and two targets: the tumor and its vasculature. Cancer Cell. 2017;31:469\u201371.","journal-title":"Cancer Cell"},{"key":"2489_CR520","doi-asserted-by":"crossref","unstructured":"Chis AA, Dobrea CM, Arseniu AM, Frum A, Rus LL, Cormos G, et al. Antibody-Drug Conjugates-Evolution and Perspectives. Int J Mol Sci. 2024;25:6969.","DOI":"10.3390\/ijms25136969"},{"key":"2489_CR521","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325.","journal-title":"Pharmacol Ther"},{"key":"2489_CR522","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jconrel.2021.12.013","volume":"341","author":"SW Fatima","year":"2022","unstructured":"Fatima SW, Khare SK. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. J Control Release. 2022;341:555\u201365.","journal-title":"J Control Release"},{"key":"2489_CR523","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00173","volume":"8","author":"R Paz-Manrique","year":"2024","unstructured":"Paz-Manrique R, Pinto JA, Gomez Moreno HL. Antibody-drug conjugates in breast cancer: toward a molecular perspective into clinical practice. JCO Precis Oncol. 2024;8:e2400173.","journal-title":"JCO Precis Oncol"},{"key":"2489_CR524","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1021\/jacsau.2c00448","volume":"2","author":"JG Felber","year":"2022","unstructured":"Felber JG, Thorn-Seshold O. 40 years of duocarmycins: a graphical structure\/function review of their chemical evolution, from SAR to prodrugs and ADCs. JACS Au. 2022;2:2636\u201344.","journal-title":"JACS Au"},{"key":"2489_CR525","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400109","volume":"19","author":"W Dong","year":"2024","unstructured":"Dong W, Wang W, Cao C. The evolution of antibody-drug conjugates: toward accurate DAR and multi-specificity. ChemMedChem. 2024;19:e202400109.","journal-title":"ChemMedChem"},{"key":"2489_CR526","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-023-00958-6","volume":"18","author":"R Ter Heine","year":"2023","unstructured":"Ter Heine R, van den Heuvel MM, Piet B, Deenen MJ, van der Wekken AJ, Hendriks LEL, et al. A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer. Target Oncol. 2023;18:441\u201350.","journal-title":"Target Oncol"},{"key":"2489_CR527","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/D0CS00310G","volume":"50","author":"SJ Walsh","year":"2021","unstructured":"Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, et al. Site-selective modification strategies in antibody-drug conjugates. Chem Soc Rev. 2021;50:1305\u201353.","journal-title":"Chem Soc Rev"},{"key":"2489_CR528","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4161\/mabs.26632","volume":"6","author":"CR Behrens","year":"2014","unstructured":"Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. MAbs. 2014;6:46\u201353.","journal-title":"MAbs"},{"key":"2489_CR529","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.764540","volume":"13","author":"N Evans","year":"2022","unstructured":"Evans N, Grygorash R, Williams P, Kyle A, Kantner T, Pathak R, et al. Incorporation of hydrophilic macrocycles into drug-linker reagents produces antibody-drug conjugates with enhanced in vivo performance. Front Pharmacol. 2022;13:764540.","journal-title":"Front Pharmacol"},{"key":"2489_CR530","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733\u20135.","journal-title":"Nat Biotechnol"},{"key":"2489_CR531","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110\u201322.","journal-title":"N Engl J Med"},{"key":"2489_CR532","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/wvn.12503","volume":"18","author":"A Whitehorn","year":"2021","unstructured":"Whitehorn A, Fu L, Porritt K, Lizarondo L, Stephenson M, Marin T, et al. Mapping clinical barriers and evidence-based implementation strategies in low-to-middle income countries (LMICs). Worldviews Evid Based Nurs. 2021;18:190\u2013200.","journal-title":"Worldviews Evid Based Nurs"},{"key":"2489_CR533","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/ajh.26576","volume":"97","author":"I Osunkwo","year":"2022","unstructured":"Osunkwo I, James J, El-Rassi F, Nero A, Minniti CP, Trimnell C, et al. Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: a comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment Survey. Am J Hematol. 2022;97:1055\u201364.","journal-title":"Am J Hematol"},{"key":"2489_CR534","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.xphs.2019.02.007","volume":"108","author":"NS Cauchon","year":"2019","unstructured":"Cauchon NS, Oghamian S, Hassanpour S, Abernathy M. Innovation in chemistry, manufacturing, and controls-a regulatory perspective from industry. J Pharm Sci. 2019;108:2207\u201337.","journal-title":"J Pharm Sci"},{"key":"2489_CR535","doi-asserted-by":"crossref","unstructured":"Raja A, Kasana A, Verma V. Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges. Mol Biotechnol. 2025;67:3345-3365.","DOI":"10.1007\/s12033-024-01270-y"},{"key":"2489_CR536","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102546","volume":"116","author":"A Tolcher","year":"2023","unstructured":"Tolcher A, Hamilton E, Coleman RL. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev. 2023;116:102546.","journal-title":"Cancer Treat Rev"},{"key":"2489_CR537","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1535-7163.MCT-23-0359","volume":"23","author":"S Schmitt","year":"2024","unstructured":"Schmitt S, Machui P, Mai I, Herterich S, Wunder S, Cyprys P, et al. Design and evaluation of phosphonamidate-linked exatecan constructs for highly loaded, stable, and efficacious antibody-drug conjugates. Mol Cancer Ther. 2024;23:199\u2013211.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR538","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1535-7163.MCT-24-0087","volume":"23","author":"HD Neff-LaFord","year":"2024","unstructured":"Neff-LaFord HD, Carratt SA, Carosino C, Everds N, Cardinal KA, Duniho S, et al. Zuch de Zafra C, Harstad EB: The Vedotin Antibody-Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles. Mol Cancer Ther. 2024;23:1483\u201393.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR539","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.MCT-22-0786","volume":"22","author":"D Toader","year":"2023","unstructured":"Toader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC, et al. Discovery and preclinical characterization of XMT-1660, an optimized B7-H4-targeted antibody-drug conjugate for the treatment of cancer. Mol Cancer Ther. 2023;22:999\u20131012.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR540","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1039\/C7TB02485A","volume":"6","author":"KF Liu","year":"2018","unstructured":"Liu KF, Liu YX, Dai L, Li CX, Wang L, Liu J, et al. A novel self-assembled pH-sensitive targeted nanoparticle platform based on antibody-4arm-polyethylene glycol-pterostilbene conjugates for co-delivery of anticancer drugs. J Mater Chem B. 2018;6:656\u201365.","journal-title":"J Mater Chem B"},{"key":"2489_CR541","doi-asserted-by":"crossref","unstructured":"Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel). 2021;14:674.","DOI":"10.3390\/ph14070674"},{"key":"2489_CR542","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234:5628\u201342.","journal-title":"J Cell Physiol"},{"key":"2489_CR543","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1535-7163.MCT-17-0672","volume":"17","author":"KR Durbin","year":"2018","unstructured":"Durbin KR, Phipps C, Liao X. Mechanistic modeling of antibody-drug conjugate internalization at the cellular level reveals inefficient processing steps. Mol Cancer Ther. 2018;17:1341\u201351.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR544","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1862452","volume":"13","author":"J Dela Cruz Chuh","year":"2021","unstructured":"Dela Cruz Chuh J, Go M, Chen Y, Guo J, Rafidi H, Mandikian D, et al. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response. MAbs. 2021;13:1862452.","journal-title":"MAbs"},{"key":"2489_CR545","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s11095-015-1729-8","volume":"32","author":"S Xu","year":"2015","unstructured":"Xu S. Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm Res. 2015;32:3577\u201383.","journal-title":"Pharm Res"},{"key":"2489_CR546","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1158\/1078-0432.CCR-18-1976","volume":"26","author":"MD Pegram","year":"2020","unstructured":"Pegram MD, Miles D, Tsui CK, Zong Y. HER2-overexpressing\/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors. Clin Cancer Res. 2020;26:775\u201386.","journal-title":"Clin Cancer Res"},{"key":"2489_CR547","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/abt\/tbae029","volume":"7","author":"VS Goldmacher","year":"2024","unstructured":"Goldmacher VS, Gershteyn IM, Kovtun Y. Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication. Antibody Therapeutics. 2024;7:351\u201360.","journal-title":"Antibody Therapeutics"},{"key":"2489_CR548","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/1078-0432.CCR-24-3468","volume":"31","author":"MA Gouda","year":"2025","unstructured":"Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, et al. Human epidermal growth factor receptor 2 loss following treatment with Trastuzumab Deruxtecan in patients with metastatic breast cancer. Clin Cancer Res. 2025;31:1268\u201374.","journal-title":"Clin Cancer Res"},{"key":"2489_CR549","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102500","volume":"113","author":"C von Arx","year":"2023","unstructured":"von Arx C, De Placido P, Caltavituro A, Di Rienzo R, Buonaiuto R, De Laurentiis M, et al. The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev. 2023;113:102500.","journal-title":"Cancer Treat Rev"},{"key":"2489_CR550","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/noae163","volume":"27","author":"AM Pereslete","year":"2025","unstructured":"Pereslete AM, Hughes ME, Martin AR, Files J, Nguyen K, Buckley L, et al. Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. Neuro Oncol. 2025;27:184\u201394.","journal-title":"Neuro Oncol"},{"key":"2489_CR551","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01797-3","volume":"39","author":"G Bon","year":"2020","unstructured":"Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchi\u00f2 C, et al. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the sePHER study. J Exp Clin Cancer Res. 2020;39:279.","journal-title":"J Exp Clin Cancer Res"},{"key":"2489_CR552","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231152842","volume":"15","author":"E Nicol\u00f2","year":"2023","unstructured":"Nicol\u00f2 E, Boscolo Bielo L, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol. 2023;15:17588359231152842.","journal-title":"Ther Adv Med Oncol"},{"key":"2489_CR553","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.601400","volume":"8","author":"JQ Wang","year":"2020","unstructured":"Wang JQ, Teng QX, Lei ZN, Ji N, Cui Q, Fu H, et al. Reversal of cancer multidrug resistance (MDR) mediated by ATP-binding cassette transporter G2 (ABCG2) by AZ-628, a RAF kinase inhibitor. Front Cell Dev Biol. 2020;8:601400.","journal-title":"Front Cell Dev Biol"},{"key":"2489_CR554","doi-asserted-by":"crossref","unstructured":"Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, et al: Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clin Cancer Res 2020, 26:1034\u20131044.\u00a0","DOI":"10.1158\/1078-0432.CCR-19-1768"},{"key":"2489_CR555","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/1535-7163.MCT-16-0219","volume":"15","author":"CH Chang","year":"2016","unstructured":"Chang CH, Wang Y, Zalath M, Liu D, Cardillo TM, Goldenberg DM. Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers. Mol Cancer Ther. 2016;15:1910\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2489_CR556","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.2174\/1389557522666220512152448","volume":"22","author":"SK Patnaik","year":"2022","unstructured":"Patnaik SK, Chandrasekar MJN, Nagarjuna P, Ramamurthi D, Swaroop AK. Targeting of ErbB1, ErbB2, and their dual targeting using small molecules and natural peptides: blocking EGFR cell signaling pathways in cancer: a mini-review. Mini Rev Med Chem. 2022;22:2831\u201346.","journal-title":"Mini Rev Med Chem"},{"key":"2489_CR557","doi-asserted-by":"crossref","unstructured":"Morch\u00f3n-Araujo D, Catani G, Mirallas O, Pretelli G, S\u00e1nchez-P\u00e9rez V, Vieito M, et al. Emerging Immunotherapy Targets in Early Drug Development. Int J Mol Sci. 2025;26:5394.","DOI":"10.3390\/ijms26115394"},{"key":"2489_CR558","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2:18\u201333.","journal-title":"Nat Cancer"},{"key":"2489_CR559","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1039\/D3CS00805C","volume":"53","author":"A Slezak","year":"2024","unstructured":"Slezak A, Chang K, Hossainy S, Mansurov A, Rowan SJ, Hubbell JA, et al. Therapeutic synthetic and natural materials for immunoengineering. Chem Soc Rev. 2024;53:1789\u20131822.","journal-title":"Chem Soc Rev"},{"key":"2489_CR560","doi-asserted-by":"crossref","unstructured":"Lei Y, Liu J, Bai Y, Zheng C, Wang D. Peptides as Versatile Regulators in Cancer Immunotherapy: Recent Advances, Challenges, and Future Prospects. Pharmaceutics. 2025;17:46.","DOI":"10.3390\/pharmaceutics17010046"},{"key":"2489_CR561","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.7150\/thno.102531","volume":"15","author":"L Wang","year":"2025","unstructured":"Wang L, Ke Y, He Q, Paerhati P, Zhuang W, Yue Y, et al. A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment. Theranostics. 2025;15:1238\u201354.","journal-title":"Theranostics"},{"key":"2489_CR562","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02024-9","volume":"23","author":"C Wang","year":"2024","unstructured":"Wang C, Zhang Y, Chen W, Wu Y, Xing D. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. Mol Cancer. 2024;23:110.","journal-title":"Mol Cancer"},{"key":"2489_CR563","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1021\/acs.jmedchem.2c00302","volume":"65","author":"A Salerno","year":"2022","unstructured":"Salerno A, Seghetti F, Caciolla J, Uliassi E, Testi E, Guardigni M, et al. Enriching proteolysis targeting chimeras with a second modality: when two are better than one. J Med Chem. 2022;65:9507\u201330.","journal-title":"J Med Chem"},{"key":"2489_CR564","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12272-023-01479-6","volume":"47","author":"S Kumari","year":"2024","unstructured":"Kumari S, Raj S, Babu MA, Bhatti GK, Bhatti JS. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions. Arch Pharm Res. 2024;47:40\u201365.","journal-title":"Arch Pharm Res"},{"key":"2489_CR565","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11912-024-01524-7","volume":"26","author":"A Ghose","year":"2024","unstructured":"Ghose A, Lapitan P, Apte V, Ghosh A, Kandala A, Basu S, et al. Antibody drug conjugates in urological cancers: a review of the current landscape. Curr Oncol Rep. 2024;26:633\u201346.","journal-title":"Curr Oncol Rep"},{"key":"2489_CR566","doi-asserted-by":"crossref","unstructured":"Justiz-Vaillant A, Pandit BR, Unakal C, Vuma S, Akpaka PE. A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2025;14:35.","DOI":"10.3390\/antib14020035"},{"key":"2489_CR567","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, Zhao X, Fu K, Zhu S, Pan C, Yang C, et al. Resistance to antibody-drug conjugates: a review. Acta Pharm Sin B. 2025;15:737\u201356.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"2489_CR568","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun. 2023;43(3):297\u2013337.","journal-title":"Cancer Commun"},{"key":"2489_CR569","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","volume":"5","author":"C Restelli","year":"2024","unstructured":"Restelli C, Ruella M, Paruzzo L, Tarella C, Pelicci PG, Colombo E. Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discov. 2024;5:234\u201348.","journal-title":"Blood Cancer Discov"},{"key":"2489_CR570","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1498391","volume":"15","author":"P Jabbarzadeh Kaboli","year":"2024","unstructured":"Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, Zerrouqi A. C-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. Front Immunol. 2024;15:1498391.","journal-title":"Front Immunol"},{"key":"2489_CR571","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512\u201322.","journal-title":"Lancet Oncol"},{"key":"2489_CR572","doi-asserted-by":"publisher","DOI":"10.1177\/11782234211002491","volume":"15","author":"\u00c9 Cipriano","year":"2021","unstructured":"Cipriano \u00c9, Mesquita A. Emerging therapeutic drugs in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2021;15:11782234211002491.","journal-title":"Breast Cancer (Auckl)"},{"key":"2489_CR573","doi-asserted-by":"crossref","unstructured":"Parneet C, Sylvia H, Marianna K, Maximilian H, Frances AS, Quincy C, et al. 695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1\/PD-L1 therapy (HUDSON). J Immunother Cancer. 2023;11:787.","DOI":"10.1136\/jitc-2023-SITC2023.0695"},{"key":"2489_CR574","first-page":"83","volume":"22","author":"Z Shi","year":"2025","unstructured":"Shi Z, Lu Y, Zhao Q, Wang Y, Qiu P. Antibody-drug conjugates in breast cancer: advances and prospects. Cancer Biol Med. 2025;22:83\u201392.","journal-title":"Cancer Biol Med"},{"key":"2489_CR575","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s12010-024-05112-0","volume":"197","author":"Y Wang","year":"2025","unstructured":"Wang Y. Durvalumab and T-DXd synergistically promote apoptosis of cholangiocarcinoma cells by downregulating EGR1 expression through inhibiting P38 MAPK pathway. Appl Biochem Biotechnol. 2025;197:1773\u201389.","journal-title":"Appl Biochem Biotechnol"},{"key":"2489_CR576","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"key":"2489_CR577","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122910","volume":"352","author":"MJ Khosravanian","year":"2024","unstructured":"Khosravanian MJ, Mirzaei Y, Mer AH, Keyhani-Khankahdani M, Abdinia FS, Misamogooe F, et al. Nectin-4-directed antibody-drug conjugates (ADCs): spotlight on preclinical and clinical evidence. Life Sci. 2024;352:122910.","journal-title":"Life Sci"},{"key":"2489_CR578","doi-asserted-by":"crossref","unstructured":"Sflakidou E, Leonidis G, Foroglou E, Siokatas C, Sarli V. Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents. Molecules. 2022;27:6632.","DOI":"10.3390\/molecules27196632"},{"key":"2489_CR579","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14712598.2021.1929168","volume":"21","author":"JL Wong","year":"2021","unstructured":"Wong JL, Rosenberg JE. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opin Biol Ther. 2021;21:863\u201373.","journal-title":"Expert Opin Biol Ther"},{"key":"2489_CR580","doi-asserted-by":"crossref","unstructured":"Rani B, Ignatz-Hoover JJ, Rana PS, Driscoll JJ. Current and Emerging Strategies to Treat Urothelial Carcinoma. Cancers (Basel). 2023;15:4886.","DOI":"10.3390\/cancers15194886"},{"key":"2489_CR581","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00494","volume":"8","author":"ES Tsang","year":"2024","unstructured":"Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, et al. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1\/2. JCO Precis Oncol. 2024;8:e2300494.","journal-title":"JCO Precis Oncol"},{"key":"2489_CR582","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/13543784.2022.2067527","volume":"31","author":"L Luo","year":"2022","unstructured":"Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022;31:607\u201331.","journal-title":"Expert Opin Investig Drugs"},{"key":"2489_CR583","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2147\/IJWH.S151194","volume":"9","author":"L Mariappan","year":"2017","unstructured":"Mariappan L, Jiang XY, Jackson J, Drew Y. Emerging treatment options for ovarian cancer: focus on rucaparib. Int J Womens Health. 2017;9:913\u201324.","journal-title":"Int J Womens Health"},{"key":"2489_CR584","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, et al. PARP inhibitors for breast cancer treatment: a review. JAMA Oncol. 2024;10:658\u201370.","journal-title":"JAMA Oncol"},{"key":"2489_CR585","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116995","volume":"281","author":"J Tao","year":"2025","unstructured":"Tao J, Gu Y, Zhou W, Wang Y. Dual-payload antibody-drug conjugates: taking a dual shot. Eur J Med Chem. 2025;281:116995.","journal-title":"Eur J Med Chem"},{"key":"2489_CR586","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162","volume":"17","author":"M Wen","year":"2025","unstructured":"Wen M, Yu A, Park Y, Calarese D, Gerber HP, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. MAbs. 2025;17:2498162.","journal-title":"MAbs"},{"key":"2489_CR587","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65860-x","volume":"10","author":"RM Hoffmann","year":"2020","unstructured":"Hoffmann RM, Mele S, Cheung A, Larcombe-Young D, Bucaite G, Sachouli E, et al. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-drug conjugates (ADCs). Sci Rep. 2020;10:8869.","journal-title":"Sci Rep"},{"key":"2489_CR588","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41568-024-00699-2","volume":"24","author":"RM Zemek","year":"2024","unstructured":"Zemek RM, Anagnostou V. Pires da Silva I, Long GV, Lesterhuis WJ: Exploiting temporal aspects of cancer immunotherapy. Nat Rev Cancer. 2024;24:480\u201397.","journal-title":"Nat Rev Cancer"},{"key":"2489_CR589","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","volume":"113","author":"RS Vasan","year":"2006","unstructured":"Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113:2335\u201362.","journal-title":"Circulation"},{"key":"2489_CR590","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11523-023-00964-8","volume":"18","author":"A Bardia","year":"2023","unstructured":"Bardia A, Viale G. HER2-low breast cancer-diagnostic challenges and opportunities for insights from ongoing studies: a podcast. Target Oncol. 2023;18:313\u20139.","journal-title":"Target Oncol"},{"key":"2489_CR591","doi-asserted-by":"publisher","first-page":"744","DOI":"10.7150\/jca.66567","volume":"13","author":"S Xie","year":"2022","unstructured":"Xie S, Wang Y, Gong Z, Li Y, Yang W, Liu G, et al. Liquid biopsy and tissue biopsy comparison with digital PCR and IHC\/FISH for HER2 amplification detection in breast cancer patients. J Cancer. 2022;13:744\u201351.","journal-title":"J Cancer"},{"key":"2489_CR592","doi-asserted-by":"crossref","unstructured":"Jauw Y, O'Donoghue J, Zijlstra J, Hoekstra O, Menke-van der Houven van Oordt C, Morschhauser F, Carrasquillo J, Zweegman S, Pandit-Taskar N, Lammertsma A, et al: 89 Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. Journal of Nuclear Medicine 2019, 60:jnumed.118.224568.","DOI":"10.2967\/jnumed.118.224568"},{"key":"2489_CR593","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00784-7","volume":"9","author":"A Ajay","year":"2025","unstructured":"Ajay A, Wang H, Rezvani A, Savari O, Grubb BJ, McColl KS, et al. Assessment of targets of antibody drug conjugates in SCLC. NPJ Precis Oncol. 2025;9:1.","journal-title":"NPJ Precis Oncol"},{"key":"2489_CR594","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156032","volume":"271","author":"Z Yao","year":"2025","unstructured":"Yao Z, Wei G, Song P, Li C, Wang G, Wen Z, et al. Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: implications for combined immunotherapy and ADC targeted therapies. Pathol Res Pract. 2025;271:156032.","journal-title":"Pathol Res Pract"},{"key":"2489_CR595","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100753","volume":"38","author":"G Dernbach","year":"2025","unstructured":"Dernbach G, Eich ML, Dragomir MP, Anders P, Jurczok N, Stief C, et al. Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management. Mod Pathol. 2025;38:100753.","journal-title":"Mod Pathol"},{"key":"2489_CR596","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/neuonc\/noad205","volume":"26","author":"S Coy","year":"2024","unstructured":"Coy S, Lee JS, Chan SJ, Woo T, Jones J, Alexandrescu S, et al. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 2024;26:458\u201372.","journal-title":"Neuro Oncol"},{"key":"2489_CR597","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113503","volume":"42","author":"Y Feng","year":"2023","unstructured":"Feng Y, Lee J, Yang L, Hilton MB, Morris K, Seaman S, et al. Engineering CD276\/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. Cell Rep. 2023;42:113503.","journal-title":"Cell Rep"},{"key":"2489_CR598","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.7150\/thno.27275","volume":"8","author":"KE Mayer","year":"2018","unstructured":"Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, et al. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics. 2018;8:6070\u201387.","journal-title":"Theranostics"},{"key":"2489_CR599","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40271-4","volume":"14","author":"R Arora","year":"2023","unstructured":"Arora R, Cao C, Kumar M, Sinha S, Chanda A, McNeil R, et al. Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response. Nat Commun. 2023;14:5029.","journal-title":"Nat Commun"},{"key":"2489_CR600","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202205395","volume":"10","author":"YM Liu","year":"2023","unstructured":"Liu YM, Ge JY, Chen YF, Liu T, Chen L, Liu CC, et al. Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination. Adv Sci (Weinh). 2023;10:e2205395.","journal-title":"Adv Sci (Weinh)"},{"key":"2489_CR601","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.","journal-title":"J Hematol Oncol"},{"key":"2489_CR602","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71\u201388.","journal-title":"Nat Rev Genet"},{"key":"2489_CR603","doi-asserted-by":"publisher","first-page":"745","DOI":"10.6004\/jnccn.2022.7006","volume":"20","author":"F Yan","year":"2022","unstructured":"Yan F, Rinn KJ, Kullnat JA, Wu AY, Ennett MD, Scott EL, et al. Response of leptomeningeal metastasis of breast cancer with a HER2\/neu activating variant to tucatinib: a case report. J Natl Compr Canc Netw. 2022;20:745\u201352.","journal-title":"J Natl Compr Canc Netw"},{"key":"2489_CR604","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55583-2","volume":"16","author":"ED Paul","year":"2025","unstructured":"Paul ED, Huraiov\u00e1 B, Valkov\u00e1 N, Matyasovska N, G\u00e1bri\u0161ov\u00e1 D, Gubov\u00e1 S, et al. The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer. Nat Commun. 2025;16:226.","journal-title":"Nat Commun"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02489-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:08:45Z","timestamp":1762168125000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02489-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":604,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02489-2","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}